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Tuberculosis (TB) remains a leading cause of death worldwide. New drug regimens were 
needed urgently to alleviate mortality and morbidity among drug-resistant TB patients. With 
the widespread use of bedaquiline (a newly developed diarylquinoline), the potential for 
drug-resistant strains requires optimal regimen selection and length of treatment. To limit 
bedaquiline resistance, information is also needed on the profile of patients who require 
extended duration of bedaquiline therapy. We examined whether previous exposure to TB 
treatment influenced the time to culture conversion (compared with no previous treatment) 
for patients receiving a drug-resistant (DR) TB regimen containing bedaquiline. We 
undertook a retrospective cohort study of DR-TB patients with documented culture 
conversion who had been initiated on a DR-TB regimen containing bedaquiline. The cohort 
was treated from April 2016 to March 2019 at Sizwe Tropical Disease Hospital. A total of 
397 files were audited, 303 new and 94 previously treated DR-TB patients. We found that up 
to two months, the two groups experienced similar rates of culture conversion, after which 
point the new-patient group displayed faster times to culture conversion. The previously 
treated group had 4.12 times the odds of culture converting after 6 months compared to the 
new group. The previously treated group thus received a longer duration of bedaquiline 
treatment than the new-patient group (p<0.001). The findings of this study substantiate the 
potential impact of previous exposure to TB treatment and establishing the influence on the 
efficacy of bedaquiline therapy. Monitoring of susceptible bedaquiline MIC in previously 
treated patients as early as two months in the event of failure to culture convert may be 
warranted. In addition further evaluation of other prescribed concurrent medication which 
may affect bedaquiline MIC would also need to be undertaken. Such monitoring can help 
prevent emergent bedaquiline drug resistance. 
 
Introduction 
Tuberculosis (TB) remains one of the leading causes of death worldwide. There is a growing 
crisis concerning drug-resistant (DR) TB, which in 2019 accounted for approximately 
500 000 incident cases. Among those cases, rifampicin-resistant (RR) or multidrug-resistant 
(MDR) forms of TB accounted for 78%[1]. Globally, 3.3% of new TB cases and 17.7% of 
previously treated cases were found to have RR or MDR TB disease [1]. Compared with 
drug-susceptible TB, MDR-TB has higher mortality and morbidity rates [1]. The treatment 
success rate for both MDR/RR-TB and extensively drug-resistant (XDR) TB is poor globally 
[1]. 
The poor success rate for DR-TB treatment is the result of high mortality, loss to follow 
up,  adverse drug reactions and frequent side effects [1]. With use of second-line 
injectables in DR-TB treatment, hearing loss has been a notable finding and warrants 
close monitoring [2]. The treatment of MDR-TB and XDR-TB is lengthy and 
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expensive[1]. These are some reasons for the poor treatment outcomes. In addition, it is 
difficult to design an effective drug regimen using four effective drugs [3]. Hence, new 
drug regimens were urgently needed to reduce mortality and morbidity among DR-TB 
patients. 
Effectiveness of bedaquiline 
Bedaqualine is a newly developed diarylquinoline with a unique mechanism of action. 
Specifically, it inhibits mycobacterial adenosine triphosphate synthase [4]. Clinical trials have 
shown benefits for reduced time to sputum conversion when bedaquiline was included in a 
treatment regimen. Bedaquiline is now included as one of the drugs in DR-TB regimens. 
With the use of bedaquiline in the current RR/MDR-TB regimen, high treatment success 
rates (87% to 90%) have been achieved [2]. 
The effectiveness of therapy is based on sputum culture conversion during the initial six- 
month treatment period [4-6]. The results of a systematic review of the therapeutic efficacy 
of bedaquiline indicated that sputum conversion was evident during the first two months of 
treatment for 48% to 84% of patients in comparison to background regimens which included 
placebo among MDR-TB and XDR-TB patients [5]. The use of bedaquiline in treatment 
regimens for baseline culture positive pulmonary MDR-TB and XDR-TB achieved culture 
conversion in 79% of patients after three months and in 97% of patients after six months of 
treatment, respectively [6]. Reduced time to sputum culture conversion is a useful early 
predictor of the successful final outcome of treatment. 
The World Health Organisation (WHO) has recommended that bedaquiline be added to an 
optimised background therapy of four effective second-line drugs; the recommendation is to 
use bedaquiline for up to 24 weeks (but not longer) [7]. The frequently noted adverse event 
identified with bedaquiline use were transaminitis, which is an increase in the liver 
transaminase  enzymes of up to three times the upper limit of normal [7]. Of note, corrected 
QT prolongation on electrocardiogram, which is considered as values above 450ms or 
increase more than 60ms from reference values is also a frequently occurring adverse event 
[7].  
There is limited evidence regarding the extended use of bedaquiline for MDR-TB and pre-
XDR-TB patients. Much of the evidence regarding the use of bedaquiline for extended 
periods has been obtained from studies that have evaluated XDR-TB treatment regimens. 
Duration of bedaquiline use was shown to be successfully extended in XDR-TB patients with 
no significant adverse effects [8]. A case series report of patients with individualised XDR-
TB regimens demonstrated the benefits of using bedaquiline, without adverse events related 
to QT interval prolongation being recorded. This was despite co-administration with 
clofazimine and moxifloxacin, two drugs that both have side-effect profiles of QTc interval 
prolongation [9]. The major concerns regarding the extended use of bedaquiline are 
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accumulative toxicity and the risk of QTc interval prolongation [10]. 
In a systematic review by Li et al., bedaquiline was shown to have favourable TB outcomes 
through advanced early bactericidal activity, but only when combined with other bactericidal 
drugs [11]. Bedaquiline should be accompanied by pyrazinamide and four second-line drugs 
which have been selected based on ‘drug susceptibility testing (DST) and/or previous use 
and/or drug resistance surveillance data’ [7]. Including bedaquiline in drug regimens that are 
suboptimal could result in selection pressure and drug-resistant mutations [12]. 
Several genetic targets that are associated with bedaquiline resistance have been identified. 
Researchers have described the presence of the Rv0678 gene mutation in evaluating 
bedaquiline therapy [13-15]. The Rv0678 mutation has demonstrated a more than four-fold 
increase for the minimum inhibitory concentrations (MIC) of bedaquiline [16]. The 
descriptions of Rv0678 mutation in isolates from TB patients without prior bedaquiline 
exposure were more pronounced in MDR-TB patients than DS-TB patients. Villelas et al. 
found the presence of Rv0678 mutations in patients with prior rifampicin exposure during 
their evaluation of mutations and the impact on treatment outcomes [15]. The significance of 
mutations requires further exploration, and the association between prior exposure to drugs 
used in first-line TB regimens and the presence of mutations warrants attention. 
Previous treatment history and efficacy of bedaquiline 
The drug resistance profiles of mycobacterium TB isolates influence the rate of conversion 
such that an inverse relationship exists between conversion rate and degree of drug 
resistance [17]. Previous TB treatment is regarded as an important risk factor for RR/MDR- 
TB, and rigorous management is required as these patients may have been infectious for a 
longer period [18]. Compared with new TB cases, previously treated patients showed a 
higher prevalence of drug resistance against first-line anti-TB drugs [19]. Studies have also 
shown that previous treatment history for TB is a risk factor for poor TB outcomes [20-21]. 
Researchers have reported varying time to culture conversion regarding RR/MDR-TB 
patients who have a history of previous TB treatment, despite the rapid bactericidal effect of 
bedaquiline [22-23]. 
Guglielmetti et al. evaluated the treatment effects of bedaquiline in MDR-TB and XDR-TB 
patients. The results showed that the time to culture conversion was adversely affected by 
the presence of lung cavities [6]. Relapses among patients with a previous TB history may 
be due to fibrotic lesions or persistent cavities [6]. A systematic review of cohort studies 
regarding bedaquiline indicated a risk of poor outcomes for patients who had lung 
cavitations and severe drug resistance ( presence of resistance to Isoniazid (KatG and inhA 
gene mutations), Rifampicin (RpoB mutation) and/or aminoglycosides (SLID gene mutation) 
and /or fluroquinolones (gyrA, gyrB gene mutations) [24-25]. However, the cohort studies 
that were reviewed included only a few patients (6.7%) who had received bedaquiline for 
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more than six months; hence, the findings provide no generalisable information about the 
extended use of bedaquiline [24]. 
Rationale 
The literature review highlighted the need to evaluate the role and effect of bedaquiline use 
for different categories of TB patients. Exploration of factors that influence the efficacy of 
bedaquiline is necessary. Identifying bedaquiline gene mutations requires routine drug 
susceptibility testing, which may not be feasible at the programme level in settings with 
limited resources. In addition, there is currently no adequate protocol for testing bedaquiline 
susceptibility[16]. With widespread bedaquiline use, the potential for selection of DR strains 
indicates the need to ensure an optimal regimen and treatment length. Previously treated TB 
patients may harbour resistant strains because of genetic mutations, and they may have 
relatively high bacterial loads due to extensive parenchymal damage. 
To limit bedaquiline resistance, information is needed on the profiles of patients who require 
extended duration of bedaquiline therapy – beyond 6 months in the absence of evidence 
from clinical trials, the cohort-reviewed data in this study provides pragmatic evidence for 
effective bedaquiline treatment duration in patients previously exposed to TB treatment. We 
investigated whether previous exposure to TB treatment influenced the time to culture 
conversion, compared with no previous TB treatment exposure, for patients who received a 
DR-TB regimen containing bedaquiline.  We undertook the comparison by reviewing the 
time to culture conversion, evaluating treatment regimens, comparison of the rate of relapse, 
comparison of duration of bedaquiline therapy and establishing the severity of disease of 
previously treated and new DR-TB patients. 
 
Materials and methods 
Study Design 
This retrospective cohort study examined data from confirmed DR-TB patients who were 
initiated on a DR-TB regimen containing bedaquiline from April 2016 to March 2019. The 
study setting was Sizwe Tropical Disease Hospital in South Africa. To account for changes 
in the DR-TB programme clinical guidelines in South Africa during the studied period, we 
evaluated drug regimens with different combinations of drugs (bedaquiline and ethionamide 
or bedaquiline and linezolid). 
Culture conversion was used as a surrogate endpoint for treatment outcome. This approach 
accounted for patients who were still on treatment or had been discharged from the hospital 
to ambulatory care at local treatment facilities at the time of the analysis. 
Study population 
Sizwe Tropical Disease Hospital is located in Gauteng and serves as a referral centre for 
complicated MDR and XDR-TB cases in this province. Only patients with bacteriologically 
confirmed DR-TB on a regimen that contained bedaquiline, with documented culture 
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conversion, were included in the study. The statistics for Sizwe Hospital for the study period 
indicated that 1 174 DR-TB patients were initiated onto a TB regimen containing 
bedaquiline. Among them, 951 patients were treated for MDR-TB, 151 were treated for pre-
XDR-TB and 72 were treated for XDR-TB. From incidence estimates in the literature, we 
anticipated that the ratio for new DR-TB patients to previously treated DR-TB patients would 
be 1:4 [26]. 
Measures 
Explanatory variables: 
Drug-resistant profiles of patients were defined using the DR-TB case definitions as per the 
South African National Department of Health [26]. An MDR-TB case was any “patient with 
bacteriologically proven TB with resistance to Rifampicin and Isoniazid with or without 
resistance to other first-line anti-TB drugs” [26]. A pre-XDR-TB case was defined as “MDR-
TB with additional resistance to either a second-line injectable or a fluoroquinolone” [25]. An 
XDR-TB case was defined as “MDR-TB that also has resistance to at least a 
fluoroquinolone and one second- line injectable (Amikacin, Kanamycin and/or 
Capreomycin)” [25]. 
Patients were categorised into “new” and “previously treated” groups based on their 
exposure to anti-TB treatment. The new group comprised DR-TB patients who had not 
received any treatment or who had received treatment for TB, MDR-TB or XDR-TB for less 
than a month. The previously treated group comprised patients who had been treated with 
first-line drugs for a month or longer, or who had been treated with at least one second-line 
drug, either with or without first-line drugs for a month or [25]. 
Severity of disease was classified according to sputum smear grading, baseline chest X-ray 
(CXR) findings and baseline resistance patterns [25;27]. Further information on the severity 
of disease is provided in S1_Protocol pdf. 
The categorization of patients based on their drugs exposure was described as follows: 
Linezolid only, Ethionamide only, no Ethionamide or Linezolid or Ethionamide and Linezolid. 
This categorization ensured that there was no overlap and that each category was 
considered independently. The combined variable ensured that the effect of both the drugs 
could be evaluated. 
Treatment regimens assessed were reflective of current and previous South African National 
TB Guidelines. Patients received either a standardised long or short DR-TB bedaquiline- 
containing regimen [25]. Other variables that could contribute to time to culture conversion 
were captured from patient records. These included sociodemographic information, medical 
conditions, HIV status and antiretroviral therapy (ART). 
Outcome variables: 
We considered sputum culture conversion, time to culture conversion and duration of 
bedaquiline treatment as clinical endpoints for this study. Details of the definitions for 
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outcome variables is provided in S1_Protocol pdf. 
 
Statistical Considerations 
Sample size and power 
We calculated the required sample size using WinPepi software (Version 11.65), set to 
detect a moderate difference between the two groups. For this purpose, we used the median 
survival times for 180 days in the previously treated group and 100 days in the new-patient 
group. These timeframes were based on the worst-case scenario described by Borisov et al. 
[25].  
The required sample sizes were determined to be 76 for the previously treated group and 
304 for the new-patient group. Hence, a total sample of 380 patients was needed to achieve 
power of 80% with hazard ratio of 0.556 and a significance of α = 0.05. Details on the 
sample size calculation are provided in S1_Protocol pdf. Patient records were 
systematically and randomly sampled, with every second patient record being selected until 
the required sample size for each group was achieved. 
Statistical analysis 
 
We used a data extraction form (see S2_CRF 001 pdf) to collect sociodemographic, clinical 
and laboratory information for each patient. Patient characteristics were summarised using 
frequencies and percentages for categorical variables and median and interquartile ranges 
for continuous variables. Chi-squared and Fischer exact tests were used to evaluate 
associations between the category of patient and the categorical outcomes. 
Time to initial conversion of sputum culture was analysed using a Kaplan-Meier survival 
curve, and the log rank test was used to test the difference between the groups. Time to 
culture conversion was truncated at 12.5 months. Only one patient was affected by this 
decision; this patient had received extended treatment due to treatment interruptions. 
Univariate logistic regression was used to assess crude associations between risk factors 
and the outcome of culture conversion after six months. The cut-off point of six months was 
derived from the methods employed in previous studies assessing bedaquiline efficacy [2, 
24]. Variables associated with the outcome at the 0.2 level of significance or were known 
from the literature to be clinically important factors for delayed culture conversion were used 
in multivariable logistic regression analysis to assess independent associations with the 
outcome of culture conversion after six months. A p-value less than or equal to 0.05 was 
considered statistically significant, and the analysis was performed with STATA software 
(version 15.0; StataCorp, Texas 2019). 
 
Ethical considerations 
This study received ethical approval from the Human Research Ethics Committee of 
Stellenbosch University (S19/09/177) (S3_HREC clearance pdf). Informed consent was not 
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required from patients. Institutional permission was received from the chief executive officer 
of Sizwe Tropical Disease Hospital (S4_Institutional permission pdf) to conduct the study 
and access patient records. 
Results 
Baseline characteristics 
This retrospective cohort study was undertaken for the period April 2016 to March 2019. In 
total, 552 files were retrieved, and 397 files were selected for auditing. Of the 155 files that 
were excluded, 46 lacked baseline culture information or had no documented culture 
conversion, 48 were cases of disseminated TB or extrapulmonary TB, two were drug- 
sensitive TB, one was mixed strain and 58 did not receive bedaquiline. Of the audited files, 
303 were new DR-TB patients and 94 were previously treated DR-TB patients. The 94 
patients in the previously treated group consisted of 68 patients with prior exposure to first- 
line TB drugs and 26 who had received second-line TB drugs. 
The profiles of patients according to their exposure groups are shown in Table 1. Age was 
not stated in one file of the previously treated group. The mean age was similar for both 
groups, and a male predominance was noted in the previously treated group (70.2%). On 
comparison of the body mass index (BMI) of both groups, 47.7% of previously treated 
patients were found to have a BMI of less than 18.5, whereas 49.5% of the new-patient 
group had BMIs between 18.5 and 25. This difference in BMI was not statistically 
significant. 
Information on comorbidities was not stated in two files of the previously treated group and 
one file of the new group. A total of 202 (27-previously treated and 175-new patients) had 
documented comorbidities  Hearing loss was the predominant comorbidity for this cohort, 
at 41.8% (165 patients out of the 394). This point is reflective of the adverse effect of 
kanamycin that warranted referral to Sizwe Tropical Disease Hospital. 
HIV status was known for all patients, and both groups had achieved successful ART 
initiation. Previous ART history was not stated in one file of the new-patient group. 
Modification of the ART regimen was documented for 68.3% (210/294) of those already on 
ART. Information on viral load was not noted in 10 files of the previously treated group and 
10 files of the new-patient group. The viral load of < 400 was used as the cut-off to indicate 
viral suppression as per the updated South African ART guidelines, 2015 [28]. Less than a 
third of patients were virologically suppressed: 31.8% in the previously treated group and 
29.3% in the new-patient group. 
We reviewed the treatment outcomes. A substantial proportion of the new group (76.5%) 
had achieved successful treatment outcomes. In the previously treated group, 24.4% of 
patients were still being treated and there was no outcome assigned to those cases at the 
time of the analysis. Of the four patients with treatment failure, three from the previously 
treated group had received extended duration of bedaquiline. 
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Table 1 Demographics and clinical characteristics 
 
Characteristics Previously treated 
group 
New-patient group p-value 
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Age  38.27 (± 11.29) years 37.02 (± 11.78) years 0.579 
Age Groups (years)   0.732 
<18 4/93 (4.3%) 10/303 (3.3%) 
18-39 51 (54.8%) 171 (56.4%) 
40-59 34 (36,6%) 115 (38%) 
60-max 4 (4.3%) 7 (2.3%) 
   
Male 66/94 (70.2%) 160/303 (52.8%) 0.003 
BMI (kg/m2)   0.053 
<18.5 42/88 (47.7%) 103/291 (35.4%) 
18.5 to <25 39/88 (44.3%) 144/291 (49.5%) 
25 to <30 2/88 (2.3%) 28/291 (9.6%) 
≥30 5/88 (5.7%) 16/291 (5.5%) 
Smoker 29/88 (33%) 67/289 (23.2%) 0.065 
Comorbidities 27/92 (29.4%) 175/302 (58%)  
Diabetes Mellitus 
3/27 (11.5%) 21/175 (12%) 
0.894 
Hypertension 
5/27 (19.2%) 16/175 (9.1%) 
0.137 
Renal 
2/27 (7.7%) 6/175 (3.4%) 
0.324 
Hearing Loss 
20/27 (74.0%) 145/175 (82.9%) 
0.358 








Change in Regimen 52/76 (68.4%) 149/218 (68.3%)  
Viral Load <400 (copies 
/mL) 
21/66 (31.8%) 61/208 (29.3%)  
Drug Resistance Profile   0.077 
MDR 63/94 (67%) 239/303 (78.8%) 


















XDR 7/94 (7.4%) 19/303 (6.2%) 
Treatment Outcomes    
Cured 27/94 (28.7%) 122/303 (40.2%) 
Treatment Complete 17/94 (18%) 110/303 (36.3%) 
Lost to Follow Up 9/94 (9.5%) 29/303 (9.5%) 
Treatment Failure 4/94 (4.2%) 0 
Died 12/94 (12.7%) 18/303 (5.9%) 
Still on Treatment 23/94 (24.4%) 10/303 (3.3%) 
Not Evaluated 0 6/303 (1.9%) 
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Transferred out 2/94 (2.1%) 8/303 (2.6%) 
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Time to culture conversion 
The Kaplan-Meier plot (Fig 1) shows that up to two months into treatment, the two groups 
experienced similar rates of culture conversion. Thereafter, the new-patient group 
experienced faster times to culture conversion. The previously treated and new groups 
almost all experienced culture conversion by Month 12. The median time to culture 
conversion for the previously treated group was 45 days (95%CI: 34–62 days) and for the 
new group 53 days (95%CI: 39–62 days). The time to culture conversion for the groups was 
compared using the log rank test, and the difference was not statistically significant (p= 
0.278). However, it was noted that the proportions culture converting by group were not 
proportional over time. 
Since all patients eventually achieved culture conversion, the time to culture conversion was 
split into two categories: i) culture converted in six months or less or ii) longer than six 
months. There was a statistically significant (p=0.004) higher proportion of culture 
conversion by six months of treatment for the new group (296/303; 97.7%) compared with 
the previously treated group (85/94; 90.4%). 
 
 
Figure 1: Kaplan-Meier plot for time to culture conversion for new and previously treated 
groups (N=397) 
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Due to the small numbers, smear grade scanty and Grade 1+ were combined for analysis 
(Table 2). The univariate analysis showed that only previously treated category of patient 
attained statistical significance but other variables of clinical significance such as age group 
<18 years, linezolid-containing regimen and smear grade 3+ showed an increased odds of 
prolonged time to culture conversion when compared to the reference category. On review 
of outcomes from the multivariable analysis (Table 2), the previously treated group displayed 
4.12 times the adjusted odds of delayed culture conversion compared with the new-patient 
group. In addition, although the difference was not statistically significant, patients younger 
than 18 years had 4.89 times the adjusted odds of longer time to culture conversion than 
patients aged 18 years or older (p=0.074). Furthermore, a smear grade of +3 was shown 
to have 2.02 times the adjusted odds of delayed time to culture conversion than a negative 
smear grade, although the difference was not statistically significant ( p=0.263). The use of 
a linezolid containing regimen was independently affected by various characteristics, with 
a change in the odds ratio on addition of other variables into the model (Table 2). 
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Table 2: Odds ratios: time to culture conversion after 6 months and risk factors (univariate 
and multivariable models)  
 
Characteristic Odds Ratio (95% CI); p-value 
Category of patient Univariate models Multivariable model 
New 1 1 
Previously Treated 4.48 (1.62–12.38); 0.004 4.12 (1.45–11.72); 0.008 
Resistance Profile   
MDR 1 
Pre-XDR (second line injectable drug 
resistance) 
 
1.21 (0.15–9.75); 0.858 
Pre-XDR (fluroquinolone resistance) 0.41 (0.05–3.20); 0.396 
BMI (kg/m2)  
< 18.5 1 
18.5 to <25 1.82 (0.55–6.04); 0.326 
25 to <30 2.52 (0.44–14.42); 0.300 
>30 1.76 (0.19–16.57); 0.620 
Gender  
Female 1 
Male 1.03 (0.38–2.82); 0.955 
Age Group (years)  
18-39 1 1 
<18  3.2 (0.64-16.07); 0.636  3.66 (0.63-21.28 ); 0.631 
40-59 0.26 (0.06-1.20); 0.084 0.27 (0.06-1.24); 0.093 
60-max 1.92 (0.23-16.36); 0.551 1.68 (0.18-16.01); 0.650 
HIV Status   
HIV negative 1 
HIV positive 0.75 (0.25–2.22); 0.605 
Regimen  
   Non linezolid-containing regimen 1 1 
 linezolid-containing regimen 2.13 (0.67–6.71); 0.199 1.53 (0.46–5.10); 0.489 
 Non ethionamide-containing regimen 1  
 ethionamide-containing regimen 1.29 (0.44–3.80); 0.641 
Smear Grade  
   Negative 1 1 
 Scanty /Grade 1+ 0.99 (0.23–4.25); 0.708 1.23 (0.28–5.48); 0.785 
 Grade 2+ 1.22 (0.23–6.46); 0.819 0.94 (0.16–5.54); 0.947 
 Grade 3+ 2.10 (0.62–7.07); 0.233 2.05 (0.58–7.19); 0.263 
CXR   
 No cavity 1 
 Single cavity 1.60 (0.52–4.91); 0.412 
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For this cohort, the previously treated group mainly received a linezolid-containing regimen 
(41.4%), whereas the new group received an ethionamide containing regimen 
(34.9%)(p=0.001) (Table 3). Further analysis showed that 33/48 (66.6%) of patients on 
linezolid (300 mg), 123/159 (77%) of patients on linezolid (600 mg) and 16/19 (84%) of 
patients on linezolid (1200 mg) achieved culture conversion within three months of starting 
treatment. Highly similar rates of relapse were found between the previously treated (3/93; 
3.2%) and new-patient groups (9/302; 3%) (p=0.904). Twelves cases of relapse during 
treatment were noted, of whom five patients were receiving bedaquiline at the time of 
relapse. 




















Previously Treated 6/94 (6.4%) 39/94 (41.5%) 18/94 (19.2%) 31/94 (33%) 0.001 
 32/303  106/303 96/303  
New (10.6%) 69/303 (22.8%) (35%) (31.7%)  
 
 
Duration of bedaquiline treatment 
Only 344 patients with a documented duration of bedaquiline therapy were included in the 
analysis. A higher proportion of the previously treated group received a longer duration of 
bedaquiline than the new group (27/75 vs 42/269 or 36% vs 15% (≥eight months of 
treatment); p<0.001). The results are summarised in Table 4. Additionally the median 
duration of bedaquiline for the new group was 183 days and for the previously treated group 
188 days (p=0.035). 
 
 
Table 4: Duration of bedaquiline treatment by category of patient (N=344) 
 













Previously treated 23/75 (30.7%) 25/75 (33.3%) 10/75 (13.3%) 17/75 (22.7%) 
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Evaluation of the 52 patients (28 new; 24 previously treated) for whom bedaquiline treatment 
was interrupted indicated that bedaquiline treatment was permanently stopped for only six 
patients (two new and four previously treated). Reasons for treatment interruption were 
primarily transient QTc interval prolongation (25/52 or 48%) and drug-induced liver injury or 
transaminitis (24/52 or 46.1%). 
Severity of disease 
Previously treated patients were shown to have more severe disease than new patients, 
based on CXR findings. Cavitatory disease was significantly associated with previous TB 
disease (p=0.006) (Table 5). A subgroup analysis of inhA resistance pattern in absence of 
KatG mutation was performed to evaluate for any between- group differences. No 
significant difference in proportion of inhA mutation was found on comparison of the two 
groups (p=0.377). The previously treated group had higher proportion of the gyra A /gyra B 
gene mutation, indicating resistance to fluoroquinolones, as compared to the new group 
(p=0.036). (Table 5). 
 
 
Table 5: Severity of disease according to category of patient 
 
Severity of Disease Previously Treated New p-value 
Baseline Smear Grade   0.683 
Negative 40/94 (42.6%) 117/303 (38.6%)  
Scanty 3/94 (3.2%) 20/303 (6.6%)  
Grade 1+ 15/94 (16%) 57/303 (18.8%)  
Grade 2+ 12/94 (12.8%) 40/303 (13.2%)  
Grade 3+ 24/94 (25.5%) 69/303 (22.8%)  
CXR   0.006 
No Cavitation 45/92 (48.9%) 203/302 (67.3%)  
Single Cavitation 28/92 (30.4%) 60/302 (19.9%)  
Multiple Cavitations 19/92 (20.7%) 39/302 (12.9%)  
Resistance Patterns    








KatG with inhA mutation 50/94 (53.1%) 158/303 (52.1%) 0.859 
RpoB 89/94 (94.6%) 301/303 (99.3%) 0.003 
SLID 11/94 (11.7%) 32/303 (10.5%) 0.731 
gyra A/gyra B 25/94 (26.5%) 51/303 (16.8%) 0.036 
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Discussion 
This study was undertaken mainly to determine whether previous TB treatment  as 
compared to no previous TB treatment, influenced the time to culture conversion for DR-TB 
patients on a bedaquiline-containing regimen. Our findings indicate that while there was no 
statistically significant difference between the two groups in terms of time to event analysis, 
when the time to culture conversion was dichotomised at six months, the previously treated 
group had a significantly higher probability of culture converting after six months than the 
new group. Further analysis of the factors that influenced the time to culture conversion 
revealed that the odds of culture conversion failure at six months was four times higher 
among previously treated patients than new patients. 
We also found that the resistance profiles, HIV status, gender and the severity of disease 
did not influence the time to culture conversion. We did not anticipate that HIV status would 
be a risk factor, as all HIV positive patients in this cohort received a modified ART regimen 
once initiated on bedaquiline. The adverse effects of efavirenz in reducing steady state 
concentrations of bedaquiline was mitigated. Thus optimal drug concentrations of 
bedaquiline were ensured [29]. Although a large proportion of the previously treated group 
were male, in keeping with the literature findings [24], gender did not influence time to 
culture conversion. A similar finding was shown in a previous study, which found no 
differences in culture conversion times among male and female DR-TB patients [30]. We 
found that patients younger than 18 years had higher odds of prolonged time to culture 
conversion although this result did not reach statistical significant. Harausz et al, in a 
systematic review of treatment outcomes of MDR-TB children found that they were more 
inclined to be older, HIV-infected and with cavitatory TB [31]. Thus, our finding does require 
further exploration. 
The median time to achieve culture conversion was similar for both groups up to the two- 
month mark, with the majority achieving culture conversion. This outcome is explained by 
the theory on the exposure–response relationship of bedaquiline in DR-TB. High-level 
bedaquiline exposure was found to have a beneficial effect within the first 20 weeks of 
treatment [32]. Bedaquiline has been shown to eliminate persistent TB bacilli as early as four 
weeks into treatment [33]. 
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For this study , most of the patients who received extended duration of bedaquiline 
treatment were in the previously treated group. A greater severity of disease was also noted 
in the previously treated group, which may have prompted clinicians to extend the duration 
of bedaquiline treatment until culture conversion. Most new patients in this study cohort 
received bedaquiline for the recommended duration of six months [4]. An earlier study [32] 
also showed that previously treated patients experienced a longer median time (up to four 
weeks longer) to culture conversion and required a longer duration of bedaquiline treatment 
to achieve conversion, compared with new patients. Guglielmetti et al. [34] similarly found 
that extended use of bedaquiline (beyond six months) was noted for previously treated 
XDR-TB, but the duration was not significantly associated with time to culture conversion. 
However, we established a significant association for the previously treated group, 
irrespective of drug resistant profile, regarding extended bedaquiline use and prolonged 
time to culture conversion. This was because our study was designed to detect a moderate 
difference between the two patient categories with sufficient statistical power. 
 
Despite the efficacy of bedaquiline treatment, we found 12 cases of treatment relapse and 
three treatment failures among previously treated patients who received extended duration 
bedaquiline. This outcome suggests that bedaquiline resistance may have been acquired by 
these patients, but further exploration is required. A retrospective study that examined MIC 
and culture conversion found that 75% of patients with prior bedaquiline exposure who 
failed to achieve culture conversion within six months displayed an Rv0678 mutation [35]. 
Thus, for patients who receive extended bedaquiline treatment, especially previously treated 
TB patients, MIC may have to be monitored to ensure susceptible bedaquiline MIC. As 
described in a recent study amongst HIV infected DR-TB patients, an association between 
emergent Rv0678 variants, failure to culture convert at 6 months and raised bedaquiline 
MICs was a notable finding [36]. 
 
Our analysis of the category of smear grade, the CXR findings and the gene mutations 
confirmed greater severity of disease among previously treated patients than new patients. 
The high percentage of fluoroquinolone resistance, in comparison to second line 
injectables, found in this study has also been documented previously [34]. Despite our 
finding of greater severity of disease in the previously treated group, this feature had no 
statistical significant influence on culture conversion. The association between severe 
disease and longer time to culture conversion was documented in earlier studies [30,37]. 
The failure to demonstrate a difference in this study may be explained by the study setting 
., only patients with severe TB disease are referred to Sizwe Tropical Disease Hospital for 
further management.  
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In both groups, treatment was interrupted because of adverse effects of bedaquiline therapy; 
however, the interruptions did not adversely influence the median duration of bedaquiline 
treatment. This finding is congruent with previous evidence that bedaquiline toxicity was 
infrequent and was reversible [2,24,38]. Pontali et al. found that QTc interval prolongation 
was common but reverted to baseline after a week [2]. 
The WHO guidelines advise using an optimal background regimen with bedaquiline, which 
includes linezolid and a fluoroquinolone [39]. In our study, most patients in the previously 
treated group received a linezolid-containing regimen. This finding may be partially 
explained by the change in the TB programme guidelines. In both groups, a high dosage 
of linezolid was associated with a high proportion of patients’ culture-converting within 
three months. The use of high dose (1200 mg) linezolid was examined in the Nix-TB trial, 
which showed that 90% of patients with highly drug-resistant TB achieved successful 
treatment outcomes [40]. We found no significant association between linezolid inclusion 
in a regimen and the time to culture conversion. The benefit of including linezolid in the 
background regimen was confirmed by the number of previously treated patients who 
achieved early culture conversion – at rates comparable to those of new patients. This 
postulation is supported by the findings of a previous study, in which the rate of culture 
conversion was twice as high in patients receiving a bedaquiline and linezolid regimen as 
compared to the standard regimen [41]. 
The retrospective design of our study implies some limitations. First, missing information 
may have affected the quality of our data, but efforts were made to review source 
documents for completeness. Second, Sizwe Tropical Disease Hospital serves as a referral 
hospital for severe forms of TB disease, and referral for initiation of bedaquiline treatment 
due to hearing loss was a criterion for our sample. Thus our findings cannot be extrapolated 
to primary health facilities that mainly treat ambulatory MDR-TB patients. 
Third, correlational analysis of the duration of bedaquiline treatment and clinical outcomes 
was not performed due to 24.4% of patients in the previously treated group still being on 
treatment. This may be reflective of the time frame for treatment initiation, which may have 
occurred later than patients in the new group. Because not all patients in the study had an 
outcome assigned, we relied on the surrogate endpoint of culture conversion to establish the 
efficacy of bedaquiline. 
Fourth, the South African National TB Guidelines underwent several changes over the study 
period. Our study reflects both the short and long course regimens but accounts only for the 
use of linezolid and ethionamide in these regimens. Hence, the impact of other newer 
agents was not examined. Furthermore, documentation of MICs for bedaquiline was not a 
feature of the TB programme, which meant we could not analyse the influence of 
bedaquiline’s MIC regarding culture conversion. Such an analysis may have been useful for 
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reviewing the extended duration of bedaquiline treatment. However, despite the above 
limitations we were able to provide pragmatic evidence on the programmatic implementation 
of bedaquiline and the influence of previous TB treatment. 
 
Conclusion 
To our knowledge, this is the first study to compare time to culture conversion across 
categories of DR-TB patients. We established that among patients receiving a bedaquiline- 
containing regimen, previously treated patients had four times the odds of delayed culture 
conversion than new patients. Most previously treated DR-TB patients who failed to culture 
convert early (by two months) were exposed to a longer duration of bedaquiline and 
experienced longer times to culture conversion than new DR-TB patients. For those in the 
previously treated group who achieved early culture conversion, inclusion of linezolid at 
higher doses in the regimen might have contributed to the outcome. 
The findings of this study contribute to the literature by exploring the potential impact of 
previous exposure to TB treatment and establishing the influence on the efficacy of current 
bedaquiline therapy. Given the extended use of bedaquiline, monitoring of susceptible 
bedaquiline MIC in previously treated patients as early as two months in the event of failure 
to culture convert may be warranted. In addition further evaluation of other prescribed 
concurrent medication which may affect bedaquiline MIC would also need to be undertaken. 
Such monitoring can help prevent emergent bedaquiline drug resistance. 
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CRediT taxonomy to describe each contribution. Read the policy and the full list of roles. 
 
 
Contributions will be published with the final article, and they should accurately reflect 
contributions to the work. The submitting author is responsible for completing this 
information at submission, and we expect that all authors will have reviewed, discussed, and 
agreed to their individual contributions ahead of this time. 
 
 





Upload a cover letter as a separate file in the online system. The length limit is 1 page. 
 
 
The cover letter should include the following information: 
 
 
Summarize the study’s contribution to the scientific literature 
Relate the study to previously published work 
Specify the type of article (for example, research article, systematic review, meta-analysis, 
clinical trial) 
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Describe any prior interactions with PLOS regarding the submitted manuscript 
Suggest appropriate Academic Editors to handle your manuscript (see the full list of 
Academic Editors) 
List any opposed reviewers 
IMPORTANT: Do not include requests to reduce or waive publication fees in the cover letter. 
This information will be entered separately in the online submission system. 
 
 
Read about publication fee assistance. 
Title page 
The title, authors, and affiliations should all be included on a title page as the first page of 
the manuscript file. 
 
 
Download our sample title, author list, and affiliations page (PDF) 
Abstract 
The Abstract comes after the title page in the manuscript file. The abstract text is also 
entered in a separate field in the submission system. 
 
 
The Abstract should: 
 
 
Describe the main objective(s) of the study 
Explain how the study was done, including any model organisms used, without 
methodological detail 
Summarize the most important results and their significance 
Not exceed 300 words 




Abbreviations, if possible 
Introduction 
The introduction should: 
 
 
Provide background that puts the manuscript into context and allows readers outside the 
field to understand the purpose and significance of the study 
Define the problem addressed and why it is important 
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Include a brief review of the key literature 
Note any relevant controversies or disagreements in the field 
Conclude with a brief statement of the overall aim of the work and a comment about whether 
that aim was achieved 
Materials and Methods 
The Materials and Methods section should provide enough detail to allow suitably skilled 
investigators to fully replicate your study. Specific information and/or protocols for new 
methods should be included in detail. If materials, methods, and protocols are well 
established, authors may cite articles where those protocols are described in detail, but the 




Supporting reproducibility with protocols 
To enhance the reproducibility of your results, we recommend and encourage you to make 
your protocols public. There are several options: 
 
 
Protocols associated with Research Articles 
Protocol documents may be uploaded as Supporting Information or linked from the Methods 
section of the article. For laboratory protocols, we recommend protocols.io. Include the DOI 
link in the Methods section of your manuscript using the following format: 
http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI]. This allows editors and reviewers 
to consult the detailed step-by-step protocol when evaluating your manuscript. You can 
choose to keep the protocol private on the protocols.io platform until your article is 
published—at which time it will be published automatically. 
 
 
Protocols published in their own right 
PLOS ONE offers two options for publishing stand-alone protocol articles: Lab Protocols that 
describe verified methodologies and Study Protocols that describe detailed plans and 
proposals for research projects. Specific guidelines apply to the submission of Lab Protocol 
and Study Protocol manuscripts. Read the detailed instructions for submitting Lab Protocols 




Results, Discussion, Conclusions 
These sections may all be separate, or may be combined to create a mixed 
Results/Discussion section (commonly labeled “Results and Discussion”) or a mixed 
Discussion/Conclusions section (commonly labeled “Discussion”). These sections may be 
further divided into subsections, each with a concise subheading, as appropriate. These 
sections have no word limit, but the language should be clear and concise. 
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Together, these sections should describe the results of the experiments, the interpretation of 
these results, and the conclusions that can be drawn. 
 
 
Authors should explain how the results relate to the hypothesis presented as the basis of the 
study and provide a succinct explanation of the implications of the findings, particularly in 
relation to previous related studies and potential future directions for research. 
 
 
PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors 





Those who contributed to the work but do not meet our authorship criteria should be listed in 
the Acknowledgments with a description of the contribution. 
 
 




PLOS journals publicly acknowledge the indispensable efforts of our editors and reviewers 
on an annual basis. To ensure equitable recognition and avoid any appearance of partiality, 
do not include editors or peer reviewers—named or unnamed—in the Acknowledgments. 
 
 
Do not include funding sources in the Acknowledgments or anywhere else in the manuscript 
file. Funding information should only be entered in the financial disclosure section of the 
submission system. 
References 
Any and all available works can be cited in the reference list. Acceptable sources include: 
 
 
Published or accepted manuscripts 
Manuscripts on preprint servers, providing the manuscript has a citable DOI or arXiv URL. 
Do not cite the following sources in the reference list: 
 
Unavailable and unpublished work, including manuscripts that have been submitted but not 
yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as 
supplementary material or deposit the data in a publicly available database. 
Personal communications (these should be supported by a letter from the relevant authors 
but not included in the reference list) 
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References are listed at the end of the manuscript and numbered in the order that they 
appear in the text. In the text, cite the reference number in square brackets (e.g., “We used 
the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the 
numbered citation (citation-sequence) method and first six authors, et al. 
 
 
Do not include citations in abstracts. 
 
 






Because all references will be linked electronically as much as possible to the papers they 
cite, proper formatting of the references is crucial. 
PLOS uses the reference style outlined by the International Committee of Medical Journal 
Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. 
Additional examples are in the ICMJE sample references. 
 
 
A reference management tool, EndNote, offers a current style file that can assist you with 
the formatting of your references. If you have problems with any reference management 
program, please contact the source company's technical support. 
Journal name abbreviations should be those found in the National Center for Biotechnology 





Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, genomic sequence cloning 
and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda (Ailuropoda 
melanoleuca). Genet Mol Res. 2011;10: 1576-1588. 
 
 
Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to SLE in South Indian 
Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Mol 




Note: A DOI number for the full-text article is acceptable as an alternative to or in addition to 
traditional volume and page numbers. When providing a DOI, adhere to the format in the 
example above with both the label and full DOI included at the end of the reference (doi: 
10.1016/j.molimm.2014.11.005). Do not provide a shortened DOI or the URL. 
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Accepted, unpublished articles Same as published articles, but substitute 
“Forthcoming” for page numbers or DOI. 
Online articles 
Huynen MMTE, Martens P, Hilderlink HBM. The health impacts of globalisation: a 





Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: University 
of Pennsylvania Press; 1992. 
 
 
Book chapters Hansen B. New York City epidemics and history for the public. In: Harden VA, 
Risse GB, editors. AIDS and the historian. Bethesda: National Institutes of Health; 1991. pp. 
21-28. 
Deposited articles (preprints, e-prints, or arXiv) 
Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et al. Amino acid 
metabolism conflicts with protein diversity. arXiv:1403.3301v1 [Preprint]. 2014 [cited 2014 
March 17]. Available from: https://128.84.21.199/abs/1403.3301v1 
 
 
Kording KP, Mensh B. Ten simple rules for structuring papers. BioRxiv [Preprint]. 2016 
bioRxiv 088278 [posted 2016 Nov 28; revised 2016 Dec 14; revised 2016 Dec 15; cited 




Published media (print or online newspapers and magazine articles) Fountain H. For 
Already Vulnerable Penguins, Study Finds Climate Change Is Another Danger. The New 
York Times. 2014 Jan 29 [Cited 2014 March 17]. Available from: 
http://www.nytimes.com/2014/01/30/science/earth/climate-change-taking-toll-on-penguins- 
study-finds.html 
New media (blogs, web sites, or other written works) Allen L. Announcing PLOS 
Blogs. 2010 Sep 1 [cited 17 March 2014]. In: PLOS Blogs [Internet]. San Francisco: PLOS 
2006 - . [about 2 screens]. Available from: http://blogs.plos.org/plos/2010/09/announcing- 
plos-blogs/. 
Masters' theses or doctoral dissertations Wells A. Exploring the development of the 
independent, electronic, scholarly journal. M.Sc. Thesis, The University of Sheffield. 1999. 
Available from: http://cumincad.scix.net/cgi-bin/works/Show?2e09 
Databases and repositories (Figshare, arXiv) Roberts SB. QPX Genome Browser 
Feature Tracks; 2013 [cited 2013 Oct 5]. Database: figshare [Internet]. Available from: 
http://figshare.com/articles/QPX_Genome_Browser_Feature_Tracks/701214 
Multimedia (videos, movies, or TV shows) Hitchcock A, producer and director. Rear 
Window [Film]; 1954. Los Angeles: MGM. 
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Supporting information 
Authors can submit essential supporting files and multimedia files along with their 
manuscripts. All supporting information will be subject to peer review. All file types can be 
submitted, but files must be smaller than 20 MB in size. 
 
 
Authors may use almost any description as the item name for a supporting information file 
as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” 
“S1 Table” and “S2 Table,” and so forth. 
 
 
Supporting information files are published exactly as provided, and are not copyedited. 
 
 
Supporting information captions 
List supporting information captions at the end of the manuscript file. Do not submit captions 
in a separate file. 
 
 
The file number and name are required in a caption, and we highly recommend including a 






S1 Text. Title is strongly recommended. Legend is optional. 
In-text citations 
We recommend that you cite supporting information in the manuscript text, but this is not a 




Read the supporting information guidelines for more details about submitting supporting 
information and multimedia files. 
Figures and tables 
Figures 
Do not include figures in the main manuscript file. Each figure must be prepared and 
submitted as an individual file. 
 
 
Cite figures in ascending numeric order at first appearance in the manuscript file. 
 
 
Read the guidelines for figures and requirements for reporting blot and gel results. 
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Figure captions 
Figure captions must be inserted in the text of the manuscript, immediately following the 
paragraph in which the figure is first cited (read order). Do not include captions as part of the 
figure files themselves or submit them in a separate document. 
 
 
At a minimum, include the following in your figure captions: 
 
 
A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, 
etc). Match the label of your figure with the name of the file uploaded at submission (e.g. a 
figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”). 
A concise, descriptive title 
The caption may also include a legend as needed. 
 
 
Read more about figure captions. 
Tables 
Cite tables in ascending numeric order upon first appearance in the manuscript file. 
 
 
Place each table in your manuscript file directly after the paragraph in which it is first cited 
(read order). Do not submit your tables in separate files. 
 
 
Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. 
Place legends, footnotes, and other text below the table. 
 
 
Read the guidelines for tables. 
Statistical reporting 
Manuscripts submitted to PLOS ONE are expected to report statistical methods in sufficient 
detail for others to replicate the analysis performed. Ensure that results are rigorously 
reported in accordance with community standards and that the statistical methods employed 
are appropriate for the study design. 
 
 
Consult the following resources for additional guidance: 
 
 
SAMPL guidelines, for general guidance on statistical reporting 
PLOS ONE guidelines, for clinical trials requirements 
PLOS ONE guidelines, for systematic review and meta-analysis requirements 
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EQUATOR, for specific reporting guidelines for a range of other study types 
Reporting of statistical methods 
In the methods, include a section on statistical analysis that reports a detailed description of 
the statistical methods. In this section: 
 
 
List the name and version of any software package used, alongside any relevant references 
Describe the technical details or procedures required to reproduce the analysis 
Provide the repository identifier for any code used in the analysis (See our code-sharing 
policy.) 
Statistical reporting guidelines: 
 
 
Identify research design and independent variables as being between- or within-subjects 
For pre-processed data: 
Describe any analysis carried out to confirm the data meets the assumptions of the analysis 
performed (e.g. linearity, co-linearity, normality of the distribution). 
If data were transformed include this information, with a reason for doing so and a 
description of the transformation performed 
Provide details of how outliers were treated and your analysis, both with the full dataset and 
with the outliers removed 
If relevant, describe how missing/excluded data were handled 
Define the threshold for significance (alpha) 
If appropriate, provide sample sizes, along with a description of how they were determined. 
If a sample size calculation was performed, specify the inputs for power, effect size and 
alpha. Where relevant, report the number of independent replications for each experiment. 
For analyses of variance (ANOVAs), detail any post hoc tests that were performed 
Include details of any corrections applied to account for multiple comparisons. If corrections 
were not applied, include a justification for not doing so 
Describe all options for statistical procedures. For example, if t-tests were performed, state 
whether these were one- or two-tailed. Include details of the type of t-test conducted (e.g. 
one sample, within-/between-subjects). 
For step-wise multiple regression analyses: 
Report the alpha level used 
Discuss whether the variables were assessed for collinearity and interaction 
Describe the variable selection process by which the final model was developed (e.g., 
forward-stepwise; best subset). See SAMPL guidelines. 
For Bayesian analysis explain the choice of prior trial probabilities and how they were 
selected. Markov chain Monte Carlo settings should be reported. 
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Reporting of statistical results 




Units of measurement. Clearly define measurement units in all tables and figures. 
Properties of distribution. It should be clear from the text which measures of variance 
(standard deviation, standard error of the mean, confidence intervals) and central tendency 
(mean, median) are being presented. 
Regression analyses. Include the full results of any regression analysis performed as a 
supplementary file. Include all estimated regression coefficients, their standard error, p- 
values, and confidence intervals, as well as the measures of goodness of fit. 
Reporting parameters. Test statistics (F/t/r) and associated degrees of freedom should be 
provided. Effect sizes and confidence intervals should be reported where appropriate. If 
percentages are provided, the numerator and denominator should also be given. 
P-values. Report exact p-values for all values greater than or equal to 0.001. P-values less 
than 0.001 may be expressed as p < 0.001, or as exponentials in studies of genetic 
associations. 
Displaying data in plots. Format plots so that they accurately depict the sample distribution. 
3D effects in plots can bias and hinder interpretation of values, so avoid them in cases 
where regular plots are sufficient to display the data. 
Open data. As explained in PLOS’s Data Policy, be sure to make individual data points, 
underlying graphs and summary statistics available at the time of publication. Data can be 
deposited in a repository or included within the Supporting Information files. 
Data reporting 
All data and related metadata underlying the findings reported in a submitted manuscript 
should be deposited in an appropriate public repository, unless already provided as part of 
the submitted article. 
 
 
See instructions on providing underlying data to support blot and gel results 
 
 
Read our policy on data availability. 
Repositories may be either subject-specific (where these exist) and accept specific types of 
structured data, or generalist repositories that accept multiple data types. We recommend 
that authors select repositories appropriate to their field. Repositories may be subject- 
specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as 
long as DOIs or accession numbers are provided and the data are at least as open as CC 
BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy 
digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of 
Approval. Large, international databases are more likely to persist than small, local ones. 
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See our list of recommended repositories. 
To support data sharing and author compliance of the PLOS data policy, we have integrated 
our submission process with a select set of data repositories. The list is neither 
representative nor exhaustive of the suitable repositories available to authors. Current 
repository integration partners include Dryad and FlowRepository. Please contact 
data@plos.org to make recommendations for further partnerships. 
 
 
Instructions for PLOS submissions with data deposited in an integration partner repository: 
 
 
Deposit data in the integrated repository of choice. 
Once deposition is final and complete, the repository will provide you with a dataset DOI 
(provisional) and private URL for reviewers to gain access to the data. 
Enter the given data DOI into the full Data Availability Statement, which is requested in the 
Additional Information section of the PLOS submission form. Then provide the URL 
passcode in the Attach Files section. 




All appropriate data sets, images, and information should be deposited in an appropriate 
public repository. See our list of recommended repositories. 
 
 
Accession numbers (and version numbers, if appropriate) should be provided in the Data 
Availability Statement. Accession numbers or a citation to the DOI should also be provided 
when the data set is mentioned within the manuscript. 
 
 
In some cases authors may not be able to obtain accession numbers of DOIs until the 
manuscript is accepted; in these cases, the authors must provide these numbers at 




As much as possible, please provide accession numbers or identifiers for all entities such as 
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InterPro 
Mouse Genome Database (MGD) 
Online Mendelian Inheritance in Man (OMIM) 
PubChem 




You can choose to upload a “Striking Image” that we may use to represent your article 
online in places like the journal homepage or in search results. 
 
 
The striking image must be derived from a figure or supporting information file from the 
submission, i.e., a cropped portion of an image or the entire image. Striking images should 
ideally be high resolution, eye-catching, single panel images, and should ideally avoid 
containing added details such as text, scale bars, and arrows. 
 
 




Striking images should not contain potentially identifying images of people. Read our policy 
on identifying information. 
 
 
The PLOS licenses and copyright policy also applies to striking images. 
Additional Information Requested at Submission 
Financial Disclosure Statement 
This information should describe sources of funding that have supported the work. It is 
important to gather these details prior to submission because your financial disclosure 
statement cannot be changed after initial submission without journal approval. If your 
manuscript is published, your statement will appear in the Funding section of the article. 
 
 
Enter this statement in the Financial Disclosure section of the submission form. Do not 
include it in your manuscript file. 
 
 
The statement should include: 
 
 
Specific grant numbers 
Initials of authors who received each award 
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Full names of commercial companies that funded the study or authors 
Initials of authors who received salary or other funding from commercial companies 
URLs to sponsors’ websites 





Data collection and analysis 
Decision to publish 
Preparation of the manuscript 
If they had no role in the research, include this sentence: “The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the manuscript.” 
 
 
If the study was unfunded, include this sentence as the Financial Disclosure statement: “The 
author(s) received no specific funding for this work." 
 
 
Read our policy on disclosure of funding sources. 
Competing interests 




All potential competing interests must be declared in full. If the submission is related to any 
patents, patent applications, or products in development or for market, these details, 
including patent numbers and titles, must be disclosed in full. 
 
 
Read our policy on competing interests. 
Manuscripts disputing published work 
For manuscripts disputing previously published work, it is PLOS ONE policy to invite a 
signed review by the disputed author during the peer review process. This procedure is 
aimed at ensuring a thorough, transparent, and productive review process. 
 
 
If the disputed author chooses to submit a review, it must be returned in a timely fashion and 
contain a full declaration of all competing interests. The Academic Editor will consider any 
such reviews in light of the competing interest. 
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Authors submitting manuscripts disputing previous work should explain the relationship 
between the manuscripts in their cover letter, and will be required to confirm that they accept 




Upon submission, authors must confirm that the manuscript, or any related manuscript, is 
not currently under consideration or accepted elsewhere. If related work has been submitted 
to PLOS ONE or elsewhere, authors must include a copy with the submitted article. 
Reviewers will be asked to comment on the overlap between related submissions. 
 
 
We strongly discourage the unnecessary division of related work into separate manuscripts, 
and we will not consider manuscripts that are divided into “parts.” Each submission to PLOS 
ONE must be written as an independent unit and should not rely on any work that has not 
already been accepted for publication. If related manuscripts are submitted to PLOS ONE, 




Read our policies on related manuscripts. 
Preprints 
PLOS encourages authors to post preprints as a way to accelerate the dissemination of 
research and supports authors who wish to share their work early and receive feedback 
before formal peer review. Deposition of manuscripts with preprint servers does not impact 
consideration of the manuscript at any PLOS journal. 
 
 
Authors posting on bioRxiv or medRxiv may submit directly to relevant PLOS journals 
through the direct transfer to journal service. 
 
 
Authors submitting manuscripts in the life sciences to PLOS ONE may opt-in to post their 
work on bioRxiv during the PLOS ONE initial submission process. 
 
 
Read more about preprints. 
 
 
Learn how to post a preprint to bioRxiv during PLOS ONE initial submission. 
Guidelines for Specific Study Types 
Registered Reports 
Submission and format requirements for Registered Report Protocols and Registered 
Reports are similar to those for a regular submission and may be specific to your study type. 
For instance, if your Registered Report Protocol submission is about a Clinical Trial or a 
Systematic Review, follow the appropriate guidelines. 
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For Registered Report Protocols: 
 
 
Provide enough methodological detail to make the study reproducible and replicable 
Confirm that data will be made available upon study completion in keeping with the PLOS 
Data policy 
Include ethical approval or waivers, if applicable 
Preliminary or pilot data may be included, but only if necessary to support the feasibility of 
the study or as a proof of principle 
For meta-analyses or Clinical Trials, use the protocol-specific reporting guidelines PRISMA- 
P or SPIRIT respectively 
For more guidance on format and presentation of a protocol, consult the sample template 




If data need to be collected, modified or processed specifically for your study, or if 
participants need to be recruited specifically for your study, then it should occur only after 
your Registered Report Protocol is accepted for publication. 
 
 
For Registered Report Research Articles: 
 
 
Report the results of all planned analyses and, if relevant, detail and justify all deviations 
from the protocol. 
The manuscript may also contain exploratory, unplanned analyses. 
Read more about Registered Report framework. 
 
Human subjects research 
All research involving human participants must have been approved by the authors’ 
Institutional Review Board (IRB) or by equivalent ethics committee(s), and must have been 
conducted according to the principles expressed in the Declaration of Helsinki. Authors 
should be able to submit, upon request, a statement from the IRB or ethics committee 
indicating approval of the research. We reserve the right to reject work that we believe has 




Subjects must have been properly instructed and have indicated that they consent to 
participate by signing the appropriate informed consent paperwork. Authors may be asked to 
submit a blank, sample copy of a subject consent form. If consent was verbal instead of 
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written, or if consent could not be obtained, the authors must explain the reason in the 
manuscript, and the use of verbal consent or the lack of consent must have been approved 
by the IRB or ethics committee. 
 
 
All efforts should be made to protect patient privacy and anonymity. Identifying information, 
including photos, should not be included in the manuscript unless the information is crucial 
and the individual has provided written consent by completing the Consent Form for 
Publication in a PLOS Journal (PDF). Download additional translations of the form from the 
Downloads and Translations page. More information about patient privacy, anonymity, and 
informed consent can be found in the International Committee of Medical Journal Editors 
(ICMJE) Privacy and Confidentiality guidelines. 
Manuscripts should conform to the following reporting guidelines: 
 
 
Studies of diagnostic accuracy: STARD 
Observational studies: STROBE 
Microarray experiments: MIAME 
Other types of health-related research: Consult the EQUATOR web site for appropriate 
reporting guidelines 
Methods sections of papers on research using human subjects or samples must include 
ethics statements that specify: 
 
 
The name of the approving institutional review board or equivalent committee(s). If approval 
was not obtained, the authors must provide a detailed statement explaining why it was not 
needed 
Whether informed consent was written or oral. If informed consent was oral, it must be 
stated in the manuscript: 
Why written consent could not be obtained 
That the Institutional Review Board (IRB) approved use of oral consent 
How oral consent was documented 
For studies involving humans categorized by race/ethnicity, age, disease/disabilities, 




Explicitly describe their methods of categorizing human populations 
Define categories in as much detail as the study protocol allows 
Justify their choices of definitions and categories, including for example whether any rules of 
human categorization were required by their funding agency 
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Explain whether (and if so, how) they controlled for confounding variables such as 
socioeconomic status, nutrition, environmental exposures, or similar factors in their analysis 
In addition, outmoded terms and potentially stigmatizing labels should be changed to more 
current, acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of 
[Western] European descent” (as appropriate); “cancer victims” should be changed to 
“patients with cancer.” 
 
 
For papers that include identifying, or potentially identifying, information, authors must 
download the Consent Form for Publication in a PLOS Journal, which the individual, parent, 
or guardian must sign once they have read the paper and been informed about the terms of 
PLOS open-access license. The signed consent form should not be submitted with the 
manuscript, but authors should securely file it in the individual's case notes and the methods 
section of the manuscript should explicitly state that consent authorization for publication is 
on file, using wording like: 
 
 
The individual in this manuscript has given written informed consent (as outlined in PLOS 
consent form) to publish these case details. 
 
 
For more information about PLOS ONE policies regarding human subjects research, see the 




Clinical trials are subject to all policies regarding human research. PLOS ONE follows the 
World Health Organization's (WHO) definition of a clinical trial: 
 
 
A clinical trial is any research study that prospectively assigns human participants or groups 
of humans to one or more health-related interventions to evaluate the effects on health 
outcomes [...] Interventions include but are not restricted to drugs, cells and other biological 
products, surgical procedures, radiologic procedures, devices, behavioural treatments, 
process-of-care changes, preventive care, etc. 
All clinical trials must be registered in one of the publicly-accessible registries approved by 
the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must 
provide the trial registration number. Prior disclosure of results on a clinical trial registry site 
will not affect consideration for publication. We reserve the right to inform authors' 




PLOS ONE supports prospective trial registration (i.e. before participant recruitment has 
begun) as recommended by the ICMJE's clinical trial registration policy. Where trials were 
not publicly registered before participant recruitment began, authors must: 
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Register all related clinical trials and confirm they have done so in the Methods section 
Explain in the Methods the reason for failing to register before participant recruitment 
Clinical trials must be reported according to the relevant reporting guidelines, i.e. CONSORT 
for randomized controlled trials, TREND for non-randomized trials, and other specialized 
guidelines as appropriate. The intervention should be described according to the 
requirements of the TIDieR checklist and guide. Submissions must also include the study 
protocol as supporting information, which will be published with the manuscript if accepted. 
 
 
Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT 
reporting guidelines appropriate to their trial design, available on the CONSORT Statement 
web site. Before the paper can enter peer review, authors must: 
 
 
The name of the registry and the registration number must be included in the Abstract. 
Provide a copy of the trial protocol as approved by the ethics committee and a completed 
CONSORT checklist as supporting information (which will be published alongside the paper, 
if accepted). This should be named S1 CONSORT Checklist. 
Include the CONSORT flow diagram as the manuscript's “Fig 1” 
Any deviation from the trial protocol must be explained in the paper. Authors must explicitly 
discuss informed consent in their paper, and we reserve the right to ask for a copy of the 
patient consent form. 
 
 
The name of the registry and the registry number must be provided in the Abstract. If the trial 





Lab Protocols consist of two interlinked components: a protocol hosted on the protocols.io 






protocols.io is a secure open access platform that specializes in laboratory protocols. It 
allows scientists to share, discover and reuse up-to-date protocol knowledge. The platform 
provides specialist tools and guidance on how to add each element of the protocol, including 




The PLOS ONE article component must comply with the general submission guidelines 
(detailed above in this article). 
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The PLOS ONE article component must also comply with the general PLOS ONE criteria for 
publication and in addition it should: 
 
 
Present a step-by-step protocol that adds value to the published literature. 
Link, in the Introduction section, to at least one supporting peer-reviewed publication in 
which the protocol was applied to generate data. 
Link, in the Materials and Methods section, to the protocol.io component, using the digital 
object identifier (DOI) and format provided by protocols.io, for example 
https://dx.doi.org/10.17504/protocols.io[ ... ]. 
Describe the appropriate controls, sample sizes and replication needed to ensure that the 
data are robust and reproducible. 
Provide the protocol as a supporting information (S1) file for printing purposes. You can 
download a PDF from protocols.io for this purpose. 
Optionally, provide minimal new data relevant to the development of the protocol e.g., for 
additional benchmarking, validation or troubleshooting purposes. 
Download a sample Lab Protocol template 
Lab Protocols describing routine methods, or extensions or modifications of routine 
methods, add little or no value to the published literature and will not be considered for 
publication. 
Manuscripts that report new methods should be submitted as research articles, not as Lab 
Protocols 
Lab Protocols are subject to the same editorial and peer review process as all other articles, 
except that the peer review process may be expedited and carried out by one internal 
Academic Editor and one external reviewer. 
 
 
Lab Protocols are eligible for both signed and published peer review. 
 
 
We encourage you to post your protocol to the protocols.io platform before submitting your 
manuscript to PLOS ONE, or at the latest, before the editorial and peer review process. This 
approach is optional, but beneficial, because: 
 
 
Your DOI is assigned on the protocols.io platform. You need this identifier to link out from 
the Material and Methods section of your manuscript. 
You can keep your protocol private on the protocols.io platform (until you are satisfied that it 
is ready for publication), but still assign a DOI. 
The protocol will be accessible to editors and reviewers during the editorial and peer review 
process. 
Stellenbosch University  https://scholar.sun.ac.za
55 of 96 
 
If you prefer to submit your manuscript to PLOS ONE before uploading your protocol to 
protocols.io, please provide your protocol as a supporting information (S1) file. You can use 
protocols.io’s editorial service at no cost: they will check and publish your protocol for you t. 
As part of PLOS ONE’s partnership with protocols.io, your waiver code for this purpose will 
be provided in the first decision letter. 
 
 






Study Protocols describe plans for conducting research projects and consist of a single 
article on PLOS ONE. 
 
 
Study Protocols must comply with the PLOS ONE general submission guidelines (detailed 
above in this article) and any guidelines specific to the related research study type. In 
addition, the protocol must: 
 
 
Relate to a research study that has not yet generated results. 
Be submitted before recruitment of participants or collection of data for the study is 
complete. 
Meet the same standards for ethics of experimentation and research integrity as the 
research study. If it involves human or animal subjects, cell lines or field sampling, or has 
potential biosafety implications, prior approval from the relevant ethics body must be 
obtained prior to submission. Please contact us if you have a valid reason for not obtaining 
approval. 






The trial must be registered prior to submission of your protocol in one of the publicly 
accessible registries approved by the WHO or ICMJE (Internation Committee of Medical 
Journal Editors). 
The name of the registry and the trial or study registration number must be included in the 
Abstract. 
A copy of the protocol that was approved by the ethics committee must be submitted as a 
supplementary information file. Please provide an addtional English translation if the original 
document is not in English. 
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A SPIRIT schedule of enrollment, interventions, and assessments must be included as the 
manuscript’s Figure 1, and a completed SPIRIT checklist must be uploaded as Supporting 
Information file S1. 
Systematic reviews and meta-analyses: 
 
 
A completed PRISMA-P checklist must be provided as a supporting information (SI) file. See 
PRISMA-P Explanation and Elaboration for more information on completing your checklist. 
Study Protocols must also comply with general PLOS ONE criteria for publication and in 
addition you should: 
 
 
include the word “Protocol” in your Title. 
include a detailed description of the planned study in the Materials and Methods section.This 
should provide sufficient methodological detail for the protocol to be reproducible and 




the aim, design, and settling 
the sample size calculation 
how data saturation will be determined (for qualitative studies) 
the characteristics of participants e.g., inclusion and exclusion criteria, sample selection 
criteria, variables to be measured, randomization and blinding criteria (where applicable), 
and how informed consent will be obtained 
how materials will be selected and used e.g., where and how they will be sourced, the 
processes, interventions, or comparisons to be used, the outcomes to be measured, and 
when and how they will be measured 
the data management plan 
safety considerations 
the type of data and statistical analyses to be used 
the status and timeline of the study, including whether participant recruitment or data 
collection has begun 
where and when the data will be made available. See our Data Availability policy for more. 
include an analysis of preliminary or pilot data, only if it is necessary to support the feasibility 
of the study or as a proof of principle. This is optional. 
we encourage authors you to register with OSF and provide the your registration number in 
the Materials and Methods section. This is optional. 
optionally add any other SI files, figures or tables that elaborate or authenticate the protocol: 
e.g., any reporting checklists applicable to your study type. 
Read the supporting information guidelines for more details about adding SI files. 
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Download our sample Study Protocol template or an OSF discipline or study-specific 
template. 
Study Protocols are subject to the same editorial and peer review process as all other 
articles, and are eligible for both signed and published peer review. 
 
 





proof of external funding. This is typically your funding approval letter and a list of the names 
and credentials of the funders who conducted the external peer review of the protocol. 
Include an English translation if needed. 
proof of ethics approval (if required). This is typically the approval or waiver letter from the 
relevant ethics body and a copy of the protocol approved by this body. 
These documents are used for internal purposes and do not form part of the published Study 
Protocol. 




If the Study Protocol describes a replication study or involves re-analysis of published work, 




We encourage you to share your Study Protocol with other researchers, either before or 
after submission. You can publish it on your website or protocols.io, or submit it for posting 







All research involving vertebrates or cephalopods must have approval from the authors' 
Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee(s), 
and must have been conducted according to applicable national and international guidelines. 
Approval must be received prior to beginning research. 
 
 
Manuscripts reporting animal research must state in the Methods section: 
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The full name of the relevant ethics committee that approved the work, and the associated 
permit number(s). 
Where ethical approval is not required, the manuscript should include a clear statement of 
this and the reason why. Provide any relevant regulations under which the study is exempt 
from the requirement for approval. 
Relevant details of steps taken to ameliorate animal suffering. 
Example ethics statement 
 
This study was carried out in strict accordance with the recommendations in the Guide for 
the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol 
was approved by the Committee on the Ethics of Animal Experiments of the University of 
Minnesota (Protocol Number: 27-2956). All surgery was performed under sodium 
pentobarbital anesthesia, and all efforts were made to minimize suffering. 
 
 
Authors should always state the organism(s) studied in the Abstract. Where the study may 




To maximize reproducibility and potential for re-use of data, we encourage authors to follow 
the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for all 
submissions describing laboratory-based animal research and to upload a completed 




Manuscripts describing research involving non-human primates must report details of 
husbandry and animal welfare in accordance with the recommendations of the Weatherall 
report, The use of non-human primates in research, including: 
 
 
Information about housing, feeding, and environmental enrichment. 
Steps taken to minimize suffering, including use of anesthesia and method of sacrifice, if 
appropriate. 
Random source animals 
Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the 
USA), shelter, or stray animals will be subject to additional scrutiny and may be rejected if 
sufficient ethical and scientific justification for the study design is lacking. 
 
 
Unacceptable euthanasia methods and anesthetic agents 
Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the 
American Veterinary Medical Association or use of an anesthesia method(s) that is widely 
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prohibited (e.g., chloral hydrate, ether, chloroform) must include at the time of initial 
submission, scientific justification for use in the specific study design, as well as confirmation 
of approval for specific use from their animal research ethics committee. These manuscripts 




Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) 
is a likely outcome or a planned experimental endpoint, must comprehensively report details 
of study design, rationale for the approach, and methodology, including consideration of 
humane endpoints. This applies to research that involves, for instance, assessment of 
survival, toxicity, longevity, terminal disease, or high rates of incidental mortality. 
 
 
Definition of a humane endpoint 
 
 
A humane endpoint is a predefined experimental endpoint at which animals are euthanized 
when they display early markers associated with death or poor prognosis of quality of life, or 
specific signs of severe suffering or distress. Humane endpoints are used as an alternative 
to allowing such conditions to continue or progress to death following the experimental 
intervention (“death as an endpoint”), or only euthanizing animals at the end of an 
experiment. Before a study begins, researchers define the practical observations or 
measurements that will be used during the study to recognize a humane endpoint, based on 
anticipated clinical, physiological, and behavioral signs. Please see the NC3Rs guidelines 
for more information. Additional discussion of humane endpoints can be found in this article: 
Nuno H. Franco, Margarida Correia-Neves, I. Anna S. Olsson (2012) How “Humane” Is Your 
Endpoint? — Refining the Science-Driven Approach for Termination of Animal Studies of 
Chronic Infection. PLoS Pathog 8(1): e1002399 doi.org/10.1371/journal.ppat.1002399. 
Full details of humane endpoints use must be reported for a study to be reproducible and for 
the results to be accurately interpreted. 
 
 
For studies in which death of an animal is an outcome or a planned experimental endpoint, 
authors should include the following information in the Methods section of the manuscript: 
 
 
The specific criteria (i.e. humane endpoints) used to determine when animals should be 
euthanized. 
The duration of the experiment. 
The numbers of animals used, euthanized, and found dead (if any); the cause of death for all 
animals. 
How frequently animal health and behavior were monitored. 
All animal welfare considerations taken, including efforts to minimize suffering and distress, 
use of analgesics or anaesthetics, or special housing conditions. 
If humane endpoints were not used, the manuscript should report: 
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A scientific justification for the study design, including the reasons why humane endpoints 
could not be used, and discussion of alternatives that were considered. 
Whether the institutional animal ethics committee specifically reviewed and approved the 
anticipated mortality in the study design. 
Observational and field studies 
Methods sections for submissions reporting on any type of field study must include ethics 
statements that specify: 
 
 
Permits and approvals obtained for the work, including the full name of the authority that 
approved the study; if none were required, authors should explain why 
Whether the land accessed is privately owned or protected 
Whether any protected species were sampled 
Full details of animal husbandry, experimentation, and care/welfare, where relevant 
Paleontology and archaeology research 
Manuscripts reporting paleontology and archaeology research must include descriptions of 
methods and specimens in sufficient detail to allow the work to be reproduced. Data sets 
supporting statistical and phylogenetic analyses should be provided, preferably in a format 
that allows easy re-use. Read the policy. 
 
 
Specimen numbers and complete repository information, including museum name and 
geographic location, are required for publication. Locality information should be provided in 
the manuscript as legally allowable, or a statement should be included giving details of the 
availability of such information to qualified researchers. 
 
 
If permits were required for any aspect of the work, details should be given of all permits that 
were obtained, including the full name of the issuing authority. This should be accompanied 
by the following statement: 
 
 
All necessary permits were obtained for the described study, which complied with all 
relevant regulations. 
If no permits were required, please include the following statement: 
 
 
No permits were required for the described study, which complied with all relevant 
regulations. 
Manuscripts describing paleontology and archaeology research are subject to the following 
policies: 
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Sharing of data and materials. Any specimen that is erected as a new species, described, or 
figured must be deposited in an accessible, permanent repository (i.e., public museum or 
similar institution). If study conclusions depend on specimens that do not fit these criteria, 
the article will be rejected under PLOS ONE's data availability criterion. 
Ethics. PLOS ONE will not publish research on specimens that were obtained without 
necessary permission or were illegally exported. 
Systematic reviews and meta-analyses 
A systematic review paper, as defined by The Cochrane Collaboration, is a review of a 
clearly formulated question that uses explicit, systematic methods to identify, select, and 
critically appraise relevant research, and to collect and analyze data from the studies that 
are included in the review. These reviews differ substantially from narrative-based reviews or 
synthesis articles. Statistical methods (meta-analysis) may or may not be used to analyze 
and summarize the results of the included studies. 
 
 
Reports of systematic reviews and meta-analyses must include a completed PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow 
diagram to accompany the main text. Blank templates are available here: 
 
 
Checklist: PDF or Word document 
Flow diagram: PDF or Word document 
Authors must also state in their “Methods” section whether a protocol exists for their 
systematic review, and if so, provide a copy of the protocol as supporting information and 
provide the registry number in the abstract. 
 
 
If your article is a systematic review or a meta-analysis you should: 
 
 
State this in your cover letter 
Select “Research Article” as your article type when submitting 
Include the PRISMA flow diagram as Fig 1 (required where applicable) 
Include the PRISMA checklist as supporting information 
Meta-analysis of genetic association studies 
Manuscripts reporting a meta-analysis of genetic association studies must report results of 
value to the field and should be reported according to the guidelines presented in Systematic 
Reviews of Genetic Association Studies by Sagoo et al. 
 
 
On submission, authors will be asked to justify the rationale for the meta-analysis and how it 
contributes to the base of scientific knowledge in the light of previously published results. 
Authors will also be asked to complete a checklist (DOCX) outlining information about the 
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justification for the study and the methodology employed. Meta-analyses that replicate 
published studies will be rejected if the authors do not provide adequate justification. 
 
 
Personal data from third-party sources 
For all studies using personal data from internet-based and other third-party sources (e.g., 
social media, blogs, other internet sources, mobile phone companies), data must be 
collected and used according to company/website Terms and Conditions, with appropriate 




Read our policy on data availability. 
In the Ethics Statement, authors should declare any potential risks to individuals or individual 
privacy, or affirm that in their assessment, the study posed no such risks. In addition, the 
following Ethics and Data Protection requirements must be met. 
 
 
For interventional studies, which impact participants’ experiences or data, the study design 
must have been prospectively approved by an Ethics Committee, and informed consent is 
required. The Ethics Committee may waive the requirement for approval and/or consent. 
 
 
For observational studies in which personal experiences and accounts are not manipulated, 
consultation with an Ethics or Data Protection Committee is recommended. Additional 
requirements apply in the following circumstances: 
 
 
If information used could threaten personal privacy or damage the reputation of individuals 
whose data are used, an Ethics Committee should be consulted and informed consent 
obtained or specifically addressed. 
If authors accessed any personal identifying information, an Ethics or Data Protection 
Committee should oversee data anonymization. If data were anonymized and/or aggregated 
before access and analysis, informed consent is generally not required. 
Note that Terms of Use contracts do not qualify as informed consent, even if they address 
the use of personal data for research. 
See our reporting guidelines for human subjects research. 
Cell lines 
Authors reporting research using cell lines should state when and where they obtained the 
cells, giving the date and the name of the researcher, cell line repository, or commercial 
source (company) who provided the cells, as appropriate. 
 
 
Authors must also include the following information for each cell line: 
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For de novo (new) cell lines, including those given to the researchers as a gift, authors must 
follow our policies for human subjects research or animal research, as appropriate. The 
ethics statement must include: 
 
 
Details of institutional review board or ethics committee approval; AND 
For human cells, confirmation of written informed consent from the donor, guardian, or next 
of kin 
For established cell lines, the Methods section should include: 
 
 
A reference to the published article that first described the cell line; AND/OR 
The cell line repository or company the cell line was obtained from, the catalogue number, 
and whether the cell line was obtained directly from the repository/company or from another 
laboratory 
Authors should check established cell lines using the ICLAC Database of Cross- 
contaminated or Misidentified Cell Lines to confirm they are not misidentified or 
contaminated. Cell line authentication is recommended – e.g., by karyotyping, isozyme 
analysis, or short tandem repeats (STR) analysis – and may be required during peer review 
or after publication. 
 
 
Blots and gels 
Please review PLOS ONE’s requirements for reporting blot and gel results and providing the 




Manuscripts reporting experiments using antibodies should include the following information: 
 
 
The name of each antibody, a description of whether it is monoclonal or polyclonal, and the 
host species. 
The commercial supplier or source laboratory. 
The catalogue or clone number and, if known, the batch number. 
The antigen(s) used to raise the antibody. 
For established antibodies, a stable public identifier from the Antibody Registry. 
The manuscript should also report the following experimental details: 
 
The final antibody concentration or dilution. 
A reference to the validation study if the antibody was previously validated. If not, provide 
details of how the authors validated the antibody for the applications and species used. 
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We encourage authors to consider adding information on new validations to a publicly 
available database such as Antibodypedia or CiteAb. 
Small and macromolecule crystal data 
Manuscripts reporting new and unpublished three-dimensional structures must include 
sufficient supporting data and detailed descriptions of the methodologies used to allow the 
reproduction and validation of the structures. All novel structures must have been deposited 




Small molecule single crystal data 
Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and 
inorganic molecules must deposit their data with the Cambridge Crystallographic Data 
Centre (CCDC), the Inorganic Crystal Structure Database (ICSD), or similar community 
databases providing a recognized validation functionality. Authors are also required to 
include the relevant structure reference numbers within the main text (e.g. the CCDC ID 
number), as well as the crystallographic information files (.cif format) as Supplementary 
Information, along with the checkCIF validation reports that can be obtained via the 




Authors reporting novel macromolecular structures must have deposited their data prior to 
initial submission with the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic 
Resonance Data Bank (BMRB), the Electron Microscopy Data Bank (EMDB), or other 
community databases providing a recognized validation functionality. Authors must include 
the structure reference numbers within the main text and submit as Supplementary 
Information the official validation reports from these databases. 
 
 
Methods, software, databases, and tools 
PLOS ONE will consider submissions that present new methods, software, databases, or 




The tool must be of use to the community and must present a proven advantage over 
existing alternatives, where applicable. Recapitulation of existing methods, software, or 
databases is not useful and will not be considered for publication. Combining data and/or 
functionalities from other sources may be acceptable, but simpler instances (i.e. presenting 
a subset of an already existing database) may not be considered. For software, databases, 
and online tools, the long-term utility should also be discussed, as relevant. This discussion 
may include maintenance, the potential for future growth, and the stability of the hosting, as 
applicable. 
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Validation 
Submissions presenting methods, software, databases, or tools must demonstrate that the 
new tool achieves its intended purpose. If similar options already exist, the submitted 
manuscript must demonstrate that the new tool is an improvement over existing options in 
some way. This requirement may be met by including a proof-of-principle experiment or 
analysis; if this is not possible, a discussion of the possible applications and some 




If the manuscript’s primary purpose is the description of new software or a new software 
package, this software must be open source, deposited in an appropriate archive, and 
conform to the Open Source Definition. If the manuscript mainly describes a database, this 
database must be open-access and hosted somewhere publicly accessible, and any 
software used to generate a database should also be open source. If relevant, databases 
should be open for appropriate deposition of additional data. Dependency on commercial 
software such as Mathematica and MATLAB does not preclude a paper from consideration, 
although complete open source solutions are preferred. In these cases, authors should 
provide a direct link to the deposited software or the database hosting site from within the 
paper. If the primary focus of a manuscript is the presentation of a new tool, such as a newly 
developed or modified questionnaire or scale, it should be openly available under a license 
no more restrictive than CC BY. 
Software submissions 
Manuscripts whose primary purpose is the description of new software must provide full 
details of the algorithms designed. Describe any dependencies on commercial products or 
operating system. Include details of the supplied test data and explain how to install and run 
the software. A brief description of enhancements made in the major releases of the 
software may also be given. Authors should provide a direct link to the deposited software 




For descriptions of databases, provide details about how the data were curated, as well as 
plans for long-term database maintenance, growth, and stability. Authors should provide a 
direct link to the database hosting site from within the paper. 
 
 
Read the PLOS policy on sharing materials and software. 
New taxon names 
Zoological names 
When publishing papers that describe a new zoological taxon name, PLOS aims to comply 
with the requirements of the International Commission on Zoological Nomenclature (ICZN). 
Effective 1 January 2012, the ICZN considers an online-only publication to be legitimate if it 
meets the criteria of archiving and is registered in ZooBank, the ICZN's official registry. 
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For proper registration of a new zoological taxon, we require two specific statements to be 
included in your manuscript. 
 
 
In the Results section, the globally unique identifier (GUID), currently in the form of a Life 
Science Identifier (LSID), should be listed under the new species name, for example: 
 
 
Anochetus boltoni Fisher sp. nov. urn:lsid:zoobank.org:act:B6C072CF-1CA6-40C7-8396- 
534E91EF7FBB 
You will need to contact Zoobank to obtain a GUID (LSID). Please do this as early as 
possible to avoid delay of publication upon acceptance of your manuscript. It is your 








The electronic edition of this article conforms to the requirements of the amended 
International Code of Zoological Nomenclature, and hence the new names contained herein 
are available under that Code from the electronic edition of this article. This published work 
and the nomenclatural acts it contains have been registered in ZooBank, the online 
registration system for the ICZN. The ZooBank LSIDs (Life Science Identifiers) can be 
resolved and the associated information viewed through any standard web browser by 
appending the LSID to the prefix “http://zoobank.org/”. The LSID for this publication is: 
urn:lsid:zoobank.org:pub: XXXXXXX. The electronic edition of this work was published in a 
journal with an ISSN, and has been archived and is available from the following digital 
repositories: PubMed Central, LOCKSS [author to insert any additional repositories]. 
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those 
of your co-authors, has its own repository, we recommend that you also deposit the 




When publishing papers that describe a new botanical taxon, PLOS aims to comply with the 
requirements of the International Code of Nomenclature for algae, fungi, and plants (ICN). 
The following guidelines for publication in an online-only journal have been agreed such that 
any scientific botanical name published by us is considered effectively published under the 
rules of the Code. Please note that these guidelines differ from those for zoological 
nomenclature, and apply only to seed plants, ferns, and lycophytes. 
 
 
Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or 
English. This does not affect the requirements for scientific names, which are still to be Latin. 
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Also effective January 2012, the electronic PDF represents a published work according to 
the ICN for algae, fungi, and plants. Therefore the new names contained in the electronic 
publication of PLOS article are effectively published under that Code from the electronic 
edition alone, so there is no longer any need to provide printed copies. 
 
 
Additional information describing recent changes to the Code can be found here. 
 
 




In the Results section, the globally unique identifier (GUID), currently in the form of a Life 
Science Identifier (LSID), should be listed under the new species name, for example: 
 
 
Solanum aspersum S.Knapp, sp. nov. [urn:lsid:ipni.org:names:77103633-1] Type: Colombia. 
Putumayo: vertiente oriental de la Cordillera, entre Sachamates y San Francisco de 
Sibundoy, 1600-1750 m, 30 Dec 1940, J. Cuatrecasas 11471 (holotype, COL; isotypes, F 
[F-1335119], US [US-1799731]). 
Journal staff will contact IPNI to obtain the GUID (LSID) after your manuscript is accepted 








The electronic version of this article in Portable Document Format (PDF) in a work with an 
ISSN or ISBN will represent a published work according to the International Code of 
Nomenclature for algae, fungi, and plants, and hence the new names contained in the 
electronic publication of a PLOS article are effectively published under that Code from the 
electronic edition alone, so there is no longer any need to provide printed copies. 
 
 
In addition, new names contained in this work have been submitted to IPNI, from where they 
will be made available to the Global Names Index. The IPNI LSIDs can be resolved and the 
associated information viewed through any standard web browser by appending the LSID 
contained in this publication to the prefix http://ipni.org/. The online version of this work is 
archived and available from the following digital repositories: [INSERT NAMES OF DIGITAL 
REPOSITORIES WHERE ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed 
Central, LOCKSS etc)]. 
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those 
of your co-authors, has its own repository, we recommend that you also deposit the 
published online article there and include the name in your article. 
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Fungal names 
When publishing papers that describe a new botanical taxon, PLOS aims to comply with the 
requirements of the International Code of Nomenclature for algae, fungi, and plants (ICN). 
The following guidelines for publication in an online-only journal have been agreed such that 
any scientific botanical name published by us is considered effectively published under the 




Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or 
English. This does not affect the requirements for scientific names, which are still to be Latin. 
 
 
Also effective January 2012, the electronic PDF represents a published work according to 
the ICN for algae, fungi, and plants. Therefore the new names contained in the electronic 
publication of PLOS article are effectively published under that Code from the electronic 
edition alone, so there is no longer any need to provide printed copies. 
 
 
Additional information describing recent changes to the Code can be found here. 
 
 




In the Results section, the globally unique identifier (GUID), currently in the form of a Life 
Science Identifier (LSID), should be listed under the new species name, for example: 
 
 
Hymenogaster huthii. Stielow et al. 2010, sp. nov. 
[urn:lsid:indexfungorum.org:names:518624] 
You will need to contact either Mycobank or Index Fungorum to obtain the GUID (LSID). 
Please do this as early as possible to avoid delay of publication upon acceptance of your 
manuscript. It is your responsibility to provide us with this information so we can include it in 
the final published paper. Effective January 2013, all papers describing new fungal species 
must reference the identifier issued by a recognized repository in the protologue in order to 
be considered effectively published. 
 
 
In the Methods section, include a sub-section called “Nomenclature” using the following 
wording. Note that this example is for taxon names submitted to MycoBank; please 




The electronic version of this article in Portable Document Format (PDF) in a work with an 
ISSN or ISBN will represent a published work according to the International Code of 
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Nomenclature for algae, fungi, and plants, and hence the new names contained in the 
electronic publication of a PLOS article are effectively published under that Code from the 
electronic edition alone, so there is no longer any need to provide printed copies. 
 
 
In addition, new names contained in this work have been submitted to MycoBank from 
where they will be made available to the Global Names Index. The unique MycoBank 
number can be resolved and the associated information viewed through any standard web 
browser by appending the MycoBank number contained in this publication to the prefix 
http://www.mycobank.org/MB/. The online version of this work is archived and available from 
the following digital repositories: [INSERT NAMES OF DIGITAL REPOSITORIES WHERE 
ACCEPTED MANUSCRIPT WILL BE SUBMITTED (PubMed Central, LOCKSS etc)]. 
All PLOS articles are deposited in PubMed Central and LOCKSS. If your institute, or those 
of your co-authors, has its own repository, we recommend that you also deposit the 




Qualitative research studies use non-quantitative methods to address a defined research 
question that may not be accessible by quantitative methods, such as people's 
interpretations, experiences, and perspectives. The analysis methods are explicit, 
systematic, and reproducible, but the results do not involve numerical values or use 
statistics. Examples of qualitative data sources include, but are not limited to, interviews, text 
documents, audio/video recordings, and free-form answers to questionnaires and surveys. 
 
 
Qualitative research studies should be reported in accordance to the Consolidated criteria 
for reporting qualitative research (COREQ) checklist or Standards for reporting qualitative 
research (SRQR) checklist. Further reporting guidelines can be found in the Equator 
Network's Guidelines for reporting qualitative research. 
 
 
You may be eligible for APC support 
Many institutional partners globally have publishing agreements with PLOS to allow their 
corresponding authors to publish with reduced or no APCs. To determine if your 
corresponding author is eligible, please visit our institutional partners page to determine 
what kind of agreement your institution has with PLOS. 
 
 
If your corresponding author is affiliated with a participating institution, she or he must follow 
the instructions below to demonstrate eligibility. 
 
 
Read the full instructions for submitting to a journal with the Flat Fee Agreement. 
If your corresponding author is not from a participating institution and requires assistance 
paying publishing fees, please consider applying for a fee waiver at submission. 
Stellenbosch University  https://scholar.sun.ac.za
70 of 96 
Title: 
Influence of previous tuberculosis treatment history on time to culture conversion for patients 
receiving a Bedaquiline containing regimen at Sizwe Tropical Disease Hospital, South Africa 
Principal Investigator: Dr Amashnee Saimen 
Institution: Clinical Epidemiology and Biostatistics 
University of Stellenbosch 




Tel: +27 21 938 …. 
Fax: +27 21 938… 
Supervisors: Mrs Tonya Esterhuizen 
Dr Xavier Padanilam 
Stellenbosch University  https://scholar.sun.ac.za
71 of 96 
Contents 
1. Abstract ........................................................................................................................... 69 
2. Background and Rationale................................................................................................ 5 
3. Objectives and Outcomes ................................................................................................. 7 
3.1 Research Question .................................................................................................... 7 
3.2 Overall Aim ................................................................................................................ 7 
3.3 Primary Objectives .................................................................................................... 7 
3.4 Secondary Objectives ................................................................................................ 7 
3.5 Primary Hypothesis ................................................................................................... 7 
4 Methods ............................................................................................................................ 8 
4.1 Study Design ............................................................................................................. 8 
Setting and Study Population ............................................................................................... 8 
4.2 Subjects ..................................................................................................................... 8 
Inclusion Criteria ............................................................................................................... 8 
Exclusion Criteria .............................................................................................................. 8 
4.3 Sampling Technique .................................................................................................. 9 
4.4 Study Procedure ........................................................................................................ 9 
4.5 Measures ................................................................................................................... 9 
Explanatory Variables ....................................................................................................... 9 
Outcome Variables: ........................................................................................................ 11 
5 Data Management Plan .................................................................................................. 11 
5.1 Data Collection ..................................................................................................... 11 
5.2 Data entering, storage and validation ...................................................................... 11 
6 Statistical Considerations ............................................................................................... 11 
7 Ethical Considerations .................................................................................................... 12 
Informed Consent ........................................................................................................... 12 
Confidentiality ................................................................................................................. 12 
Standard of Care ............................................................................................................ 12 
Inclusion of Women ........................................................................................................ 13 
Exclusion of Children ...................................................................................................... 13 
Conflict of Interest ........................................................................................................... 13 
8 Study Timelines .............................................................................................................. 13 
9 Study Limitations ............................................................................................................ 13 
10 Feasibility .................................................................................................................... 14 
11 Future Directions ......................................................................................................... 14 
12 Study Team ................................................................................................................. 14 
Stellenbosch University  https://scholar.sun.ac.za
72 of 96 
13 Institutional Research Environment............................................................................. 14 
14 Budget ......................................................................................................................... 14 
15 References .................................................................................................................. 16 
1. Abstract
Tuberculosis remains one of the leading causes of death worldwide. There is a growing 
crisis concerning the number of drug resistant TB cases. New drug regimens were urgently 
needed to improve mortality and morbidity among drug resistant TB patients. Bedaqualine is 
a newly developed diarylquinoline with a unique mechanism of action. . Studies have 
reported varying time to culture conversion regarding RR/MDR-TB patients with history of 
previous TB treatment. The Rv0678 mutation found in patients with prior Rifampicin 
exposure has demonstrated a more than four-fold increase in the minimum inhibitory 
concentrations of Bedaquiline. Previously treated TB patients may be more likely to have 
higher bacterial load due to extensive parenchymal damage. This study will provide 
information on effective Bedaquiline treatment duration for those previously exposed to TB 
treatment. 
Aim: To determine whether previous exposure to TB treatment influences the time to culture 
conversion as compared to no previous TB treatment exposure in patients receiving a DR- 
TB regimen containing Bedaquiline. 
Primary Objective: To compare the time to culture conversion for previously treated and 
new DR-TB patients receiving the Bedaquiline containing regimen. 
Secondary Objectives: 
1. To evaluate treatment regimens at time of culture conversion for previously treated and
new DR-TB patients
2. To compare the rate of relapse in previously treated and new DR-TB patients receiving
the Bedaquiline containing regimen.
3. To compare the duration of Bedaquiline therapy in previously treated and new DR-TB
patients
4. To establish the severity of disease of previously treated and new DR-TB patients.
Setting and Study Population: The study will be conducted at Sizwe Tropical Disease 
Hospital in Gauteng Province. Sizwe Tropical Disease Hospital serves as a referral centre 
for complicated MDR/XDR-TB cases in Gauteng. 
Study Design: A retrospective cohort study will be undertaken for confirmed DR-TB patients 
who were initiated on DR-TB regimen containing Bedaquiline from April 2016 to March 2019. 
Inclusion Criteria 
Bacteriologically confirmed DR-TB 
All patients receiving DR-TB Regimens containing Bedaquiline including new DR-TB with no 
previous history of TB treatment 
Documented culture conversion 
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Variables: Culture Conversion; Time to culture conversion; Duration of Bedaquiline 
treatment 
Sampling Technique: 
The group sample sizes were determined to be 76 (Previous treatment group) and 304 (New 
treatment group), power of 80% with a level of significance of α 0.05. 
Time Frame: The study will be conducted from June 2020 to November2020 
2. Background and Rationale
Tuberculosis remains one of the leading causes of death worldwide. There is a growing 
crisis concerning the number of drug resistant TB cases, 558 000-incident cases in 2017 of 
which Rifampicin Resistant (RR) /Multi Drug Resistant (MDR)-TB accounted for 82%.1 It was 
shown that globally 3.5% of new TB cases and 18% of previously treated cases had 
RR/MDR-TB disease.1 On comparison to drug-susceptible TB, MDR-TB has higher mortality 
and morbidity rates, with poor treatment success rate for both MDR/RR-TB and Extensively 
Drug Resistant (XDR)-TB globally.1 
The low success rate in drug resistant TB was as a result of high mortality, loss to follow up 
and adverse drug reactions.1 The treatment of MDR-TB and XDR-TB is long, expensive and 
with frequent side effects.1 These are some of the reasons for poor treatment outcomes. In 
addition, there is difficulty in designing a suitable drug regimen with four effective drugs.2 
Thus, new drug regimens were urgently needed to improve mortality and morbidity among 
drug resistant TB patients. 
Effectiveness of Bedaquiline 
Bedaqualine is a newly developed diarylquinoline with a unique mechanism of action, 
specifically inhibiting mycobacterial adenosine triphosphate synthase.3 Clinical trials have 
shown the benefit of reduced time to sputum conversion when Bedaquiline was included in a 
treatment regimen. Bedaquiline has been included as one of the drugs in drug resistant TB 
regimens. With the use of Bedaquiline in the current RR/MDR-TB regimen high treatment 
success rates (87-90%) have been achieved.4 
The effectiveness of therapy is based on sputum culture conversion during the initial 6- 
month treatment period. From the results of a systematic review of the therapeutic efficacy 
of Bedaquiline, sputum conversion was demonstrated during the first 2 months of treatment 
(achieved in 48% to 84% of patients).5 The use of Bedaquiline in treatment regimens for 
culture positive pulmonary MDR-TB and XDR-TB achieved culture conversion in 79% of 
patients after 3 months and in 97 % of patients after 6 months of treatment respectively.6 
Reduced time to sputum culture conversion has been a useful early predictor of successful 
final treatment outcome. 
The WHO has recommended that Bedaquiline be added to an optimised background 
therapy of four effective second-line drugs..7 . Much of the evidence on use of Bedaquiline 
for extended periods have been from studies evaluating XDR- TB treatment regimens. 
Duration of Bedaquiline use was shown to be successfully extended in XDR-TB with no 
significant adverse effects.8 A case series report of patients with individualised XDR- TB 
regimens showed a benefit with the use of Bedaquiline with no adverse events of QT 
prolongation being recorded despite co-administration with Clofazimine and Moxfloxicin 
(both drugs having side effects profile of QT prolongation).9 The major concerns regarding 
extended use of Bedaquiline is accumulative toxicity and risk of QT prolongation.10 
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In a systematic review conducted by Li et al, Bedaquiline was shown to have favourable TB 
outcomes with advanced early bactericidal activity only when combined with other 
bactericidal drugs.11  Bedaquiline, thus should be accompanied by an effective background 
regimen in order to ensure improved treatment outcomes. Including Bedaquiline in drug 
regimens that are suboptimal could result in selection pressure and drug resistant 
mutations.12 Several genetic targets that are associated with Bedaquiline resistance have 
been identified. Several studies have described the presence of the Rv0678 gene mutation 
on evaluating Bedaquiline therapy. 13 ,14, 15 
The Rv0678 mutation has demonstrated a more than four-fold increase in the minimum 
inhibitory concentrations of Bedaquiline.16 The description of Rv0678 mutations in isolates 
from MDR-TB patients without prior Bedaquiline exposure were more pronounced in MDR- 
TB than DS-TB patients. Villelas et al found the presence of Rv0678 mutations in patients 
with prior Rifampicin exposure during their evaluation of mutations and the impact on 
treatment outcomes.15 Although the significance of mutations still requires further 
exploration, the association between prior exposure to drugs used in first line TB regimens 
and the presence of mutations warrants attention. 
Previous treatment history influencing efficacy of Bedaquiline 
It has been shown that the drug resistance profiles of Mtb isolates influences the rate of 
conversion, an inverse relation between conversion rate and degree of drug resistance 
exists.17 Thus, previous TB treatment is regarded as an important risk factor for RR/MDR- 
TB. Rigorous management is required as these patients may have been infectious for a 
longer period.18 When compared to new TB patients, previously treated TB patients showed 
a higher prevalence of drug resistance against first line anti TB drugs .19 Studies have also 
shown that previous treatment history of TB is a risk factor for poor TB outcomes. 20,21 
Varying time to culture conversion regarding RR/MDR-TB patients with history of previous 
TB treatment despite rapid bactericidal effect of Bedaquiline has also been demonstrated. 
22,23 
A study by Guglielmetti et al evaluating treatment effects of Bedaquiline in MDR-TB and 
XDR-TB patients,showed that the time to culture conversion was adversely affected by the 
presence of lung cavities.6 Relapse in patients with previous TB history may be due to 
fibrotic lesions or persistent cavities. A systematic review of cohort studies on the use of 
Bedaquiline showed that there was risk of poor outcomes in patients with lung cavitations 
and more severe drug resistance. 24 The cohort studies reviewed however consisted of only 
a few numbers of patients (6.7%) who received Bedaquiline for more than 6 months and 
therefore did not provide information on the role of extended use of Bedaquiline.26 
Rationale 
The literature reviewed highlights the need for evaluation of the role and the effect of 
Bedaquiline use with different categories of TB patients. Exploration of factors influencing 
efficacy of Bedaquiline is important. Identifying Bedaquiline gene mutations requires routine 
drug susceptibility testing which may not be feasible at a programmatic level in resource- 
limited settings. In addition, there is currently no adequate protocol testing Bedaquiline 
susceptibility in low to middle income countries.16 With widespread Bedaquiline use, the 
potential for selection of drug resistant strains signifies the importance of ensuring optimal 
regimen selection and length of treatment. Previously treated TB patients may harbour 
resistant strains as a result of genetic mutations and may be more likely to have higher 
bacterial load due to extensive parenchymal damage. In order to limit Bedaquiline 
resistance, information is needed on the profile of patients requiring extended duration of 
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Bedaquiline therapy beyond 24 weeks. In the absence of evidence from clinical trials, the 
cohort-reviewed data from this study will provide pragmatic evidence on effective 
Bedaquiline treatment duration for those previously exposed to TB treatment. The findings of 
this study will contribute to the literature by substantiating the potential impact of previous 
exposure to TB treatment on the efficacy of Bedaquiline therapy. This study will also draw 
focus on the importance of the choice of background regimens when extended duration of 
Bedaquiline is required and the possible need for monitoring of minimum inhibitory 
concentrations for this subgroup. 
3. Objectives and Outcomes
3.1 Research Question 
In patients receiving the DR-TB regimen containing Bedaquiline, does previous exposure to 
TB treatment as compared to no previous TB treatment exposure, increase the time to 
culture conversion at Sizwe Tropical Disease Hospital from April 2016 to March 2019. 
3.2 Overall Aim 
To determine whether previous exposure to TB treatment influences the time to culture 
conversion as compared to no previous TB treatment exposure in patients receiving a 
DR-TB regimen containing Bedaquiline. 
3.3 Primary Objectives 
1. To compare the time to culture conversion for previously treated and new DR-TB
patients receiving the Bedaquiline containing regimen.
3.4 Secondary Objectives 
1. To evaluate treatment regimens (linezolid or ethionamide containing regimens) at time of
culture conversion for previously treated and new DR-TB patients
2. To compare the rate of relapse in previously treated and new DR-TB patients receiving
the Bedaquiline containing regimen.
3. To compare the duration of Bedaquiline therapy in previously treated and new DR-TB
patients
4. To establish the severity of disease of previously treated and new DR-TB patients.
3.5 Hypothesis 
Scientific Hypothesis: It is anticipated that in patients receiving DR-TB treatment 
containing Bedaquiline, previously treated TB patients will require a longer duration of 
treatment to achieve culture conversion as compared to new DR-TB patients. 
Primary Statistical Hypothesis 
HA: Previous exposure to TB treatment will be associated with increased time to culture 
conversion in patients receiving DR-TB regimen containing Bedaquiline as compared to 
newly diagnosed DR-TB patients. 
HO: Previous exposure to TB treatment will not be associated with increases time to 
culture conversion in patients receiving DR-TB regimen containing Bedaquiline as 
compared to newly diagnosed DR-TB patients. 
Secondary Statistical Hypothesis 
Objective 1 
HA: Time to culture conversion will differ depending on treatment regimen 
Ho: Time to culture conversion will not differ depending on treatment regimen 
Objective 2 
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HA: The rate of relapse will be greater in the previously treated as compared to new DR- 
TB patients 
HO: The rate of relapse will be the same in the previously treated and new DR-TB 
patients 
Objective 3 
HA: The duration of Bedaquiline therapy will be longer in the previously treated as 
compared to new DR-TB patients 
HO: The duration of Bedaquiline therapy will be the same in the previously treated and 
new DR-TB patients 
Objective 4 
HA: DR-TB patients with previous exposure to TB treatment will have greater severity of 
disease than new patients 
HO: DR-TB patients with previous exposure to TB treatment will have the same severity 
of disease as new patients 
4 Methods 
4.1 Study Design 
A retrospective cohort study will be undertaken for confirmed DR-TB patients who were 
initiated on DR-TB regimen containing Bedaquiline from April 2016 to March 2019 at 
Sizwe Tropical Disease Hospital. The choice of study design is appropriate as strict 
eligibility criteria are maintained for consideration of Bedaquiline therapy, thus a 
retrospective cohort study will ensure an adequate sample size will be reached. The time 
period will allow for assessment of culture conversion status for majority of the patients. 
This study will account for changes to the DR-TB programme clinical guideline in South 
Africa from 2016 to 2019. It is anticipated that patients diagnosed with DR-TB during this 
period would have been initiated on a combination of Bedaquiline and Ethionamide or 
Bedaquiline and Linezolid and a suitable background regimen. Diagnosis of drug 
resistant TB is based on GeneXpert MTB Rif assay/ GeneXpert Ultra assay (since 
November 2017), Culture, Drug Susceptibility Testing or Line Probe Assay testing 
results. Drug susceptibility testing is performed by the National Health Laboratory 
Services for the following drugs: Rifampicin; Isoniazid; Second line injectables; and 
fluoroquinolones. All patients initiated on the Bedaquiline containing regimen are 
monitored for ECG changes and adverse drug reactions. Monitoring of the QT interval on 
ECG, with prolongation of the corrected QT defined as a value >450 ms in males or > 
470ms in females or > 60ms increase from baseline would be considered as significant 
and warrants interruption or stopping of Bedaquiline therapy. 
Sputum culture conversion is considered as one negative culture from a positive 
baseline culture result as per clinical protocol at Sizwe Tropical Disease Hospital. The 
date of the sputum collection of the negative culture will be regarded as the date of 
culture conversion. Culture conversion will be used as a surrogate end point for 
treatment outcome to account for patients who are still currently on treatment or have 
been discharged from Sizwe Tropical Disease Hospital to ambulatory care at local 
treatment facilities. 
Setting and Study Population 
The study will be conducted at Sizwe Tropical Disease Hospital in Gauteng Province. 
Sizwe Tropical Disease Hospital serves as a referral centre for complicated MDR/XDR- 
TB cases in Gauteng. Patients are initiated on treatment in-hospital and discharged on 
culture conversion for follow-up at local health facility. The study population will consist 
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Bacteriologically confirmed DR-TB 
All patients receiving DR-TB Regimens containing Bedaquiline including new DR-TB 
patients with no previous history of TB treatment 
Documented culture conversion 
Exclusion Criteria 
No culture results at start of treatment 
Negative culture results at start of treatment 
Extrapulmonary DR-TB 
Mixed Infection (i.e. Drug Sensitive and Drug Resistant TB or Non Tuberculous 
Mycobacteria (NTM) and Drug Resistant TB) 
GeneXpert MTB Rif assay negative at start of treatment 
4.3 Sampling Technique 
All patients initiated on DR-TB regimen containing Bedaquiline from April 2016 will be 
identified for review. The statistics for Sizwe Tropical Disease Hospital for the period April 
2016 to March 2019 showed that a total of 1174 DR-TB patients were initiated on TB 
regimen containing Bedaquiline. Of the DR-TB patients, 951 were treated for MDR-TB, 151 
were treated for pre-XDR TB and 72 were treated for XDR-TB. From incidence estimates in 
the literature, it is anticipated that the ratio for new DR-TB patients to previously treated DR- 
TB patients will be 1:4. 25 
4.4 Study Procedure 
Suitable patient profiles meeting the inclusion criteria will be identified from the TB 
Registers. A list of patient file numbers will then be finalised for file will be retrieved by the 
hospital clerks. This method will ensure that the patient privacy and confidentiality will be 
maintained. Anonymised patient data will then be extracted from files. Patient’s 
demographic information, category of TB patient, information on severity of TB disease, 
treatment regimens and treatment response parameters (sputum/culture conversion, 
adverse events, and treatment outcomes) will be extracted. The patient information will be 
captured on Case Report Forms (CRF). CRFs will be filed in secure storage area. 
4.5 Measures 
Explanatory Variables 
DR-TB Case Definitions:26 
MDR-TB case is defined as “a patient with bacteriologically proven TB with resistance to 
Rifampicin and Isoniazid with or without resistance to other first-line anti-TB drugs”. 
Pre XDR-TB case is defined as “MDR-TB with additional resistance to either a second-line 
injectable or a fluoroquinolone”. 
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XDR-TB case is defined as “MDR-TB that also has resistance to at least a fluoroquinolone 
and one second-line injectable (Amikacin, Kanamycin and/or Capreomycin)”. 
Patients will be categorised as follows:26 
Category I: New “A patient who has received no anti- 
tuberculosis treatment for TB, MDR- or 
XDR-TB or received less than one month of 
anti-tuberculosis drugs” 
Category II: Previously treated with first-line 
drugs only 
“Patient who has been treated for one 
month or more for TB with only first-line 
drugs”. 
Category III: Previously treated with 
second-line drugs 
“Patient who has been treated for one 
month or more for TB or DR-TB with one or 
more second-line, with or without first-line 
drugs”. 
Severity of disease: 
Severity of disease will be classified according to sputum smear grading, baseline CXR 
findings and baseline resistance patterns.27 
Sputum smear will be graded on ZN Stain as follows: 
“Negative: No acid-fast bacilli (AFB) observed” 
“Scanty: 1-9 AFB in 100 fields” 
“1+:10-99 AFB in 100 fields” 
“2+:1–10 AFB in 1 field” 
“3+: > 10 AFB in 1 field “ 
CXR findings will be categorised as 
cavitatory –single 
cavitatory - multiple 
non-cavitatory. 
Baseline resistance patterns will be assessed (if documented in laboratory report) as 
presence of:26 
Resistance to Isoniazid: inhA gene mutation 
KatG gene mutation 
Resistance to Rifampicin: RpoB gene mutation 
Resistance to second line injectables: rrs gene mutation 
eis gene mutation 
Resistance to Fluoroquinolones: gyra A 
gyra B 
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Treatment regimen assessed will be reflective of current and previous South African 
National TB guidelines.26 
Standardised DR-TB Bedaquiline containing Regimens: 
1. Short Regimen:
Duration: 9-11 months 
Duration of Intensive Phase: 4 months 
Duration of Extended Intensive Phase: 6 months 
Current Standard Drug Regimen: Linezolid (LZD) (first two months) 
+Bedaquiline (BDQ) + Levofloxacin (LFX)+ Clofazimine (CFZ)+ Isoniazid
(INH) (high dose) + Pyrazinamide (Z) + Ethambutol (E)
Previous Standard Drug Regimen: 
Ethionamide (Eto) + BDQ+LFX+ CFZ + IINH (high dose) + Z +E 
2. Long Regimen:
Duration: 18-20 months 
Duration of Intensive Phase: 6 months 
Duration of Extended Intensive Phase: 8 months 
Current Standard Drug Regimen: LZD + BDQ+LFX+CFZ+Terizadone (TRD) 
Previous Standard Drug Regimen: 
Eto+BDQ+LFX+CFZ+TRD 
Other factors (confounders) that may contribute to time to culture conversion will be 
extracted from patient records: 
Sociodemographic information such as Gender, Age, Weight, smoking history will be 
collected from patient records. 
History of other medical conditions such as Diabetes Mellitus, Hypertension, Renal Disease, 
Hearing Loss will be collected from patient records. 
HIV status information and relevant information pertaining to Anti- Retroviral therapy start 
date , Anti -retroviral Therapy regimen, any modifications to Anti -retroviral regimen and last 
viral load will be collected from patient records where applicable. 
Outcome Variables: 
Clinical endpoints will be considered as follows: 
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Sputum culture conversion is defined as one consecutive negative culture as per 
clinical protocols for Sizwe Tropical Medicine Hospital and will reflect the date of 
sputum collection. 
Time to culture conversion will be the date from treatment initiation to date of culture 
conversion. 
Duration of Bedaquiline treatment will be the date of Bedaquiline initiation to date of 
stopping Bedaquiline treatment. 
Specific Measurements: 
DR-TB Treatment start date: Documented date of treatment initiation. 
Evidence of relapse: Positive culture results following documented culture 
conversion. 
Culture conversion date: Documented date of negative culture result with subsequent 
negative culture outcomes. 
Time to culture conversion (days): Calculated period from date of treatment initiation 
to date of culture conversion. 
Bedaquiline start date: Documented date of Bedaquiline initiation. 
Bedaquiline end date: Documented date of stopping Bedaquiline. 
Duration of Bedaquiline treatment (days): Calculated period from date of initiation to 
stopping Bedaquiline. 
Specific information to be extracted from patient records for each objective has been 
outlined below: 
Primary Objective: To compare the time to culture conversion for previously treated and 
new DR-TB patients receiving the Bedaquiline containing regimen 
DR-TB patients receiving the Bedaquiline containing regimen will be categorised as new or 
previously treated TB patients according to DR-TB category definitions. Data on DR-TB 
treatment start date and culture conversion date will be extracted from patient records and 
the time to culture conversion (in days) will be calculated from the data. 
Secondary Objectives: 
1. To evaluate treatment regimens ( Linezolid or ethionamide containing regimens) at
time of culture conversion for previously treated and new DR-TB patients
DR-TB patients receiving the Bedaquiline containing regimen will be categorised as new or 
previously treated according to DR-TB category definitions. Information on the individual 
drugs used in the treatment regimen at the time of culture conversion will be extracted for 
each patient. Additional information on the drug dosage of Linezolid at the time of culture 
conversion will also be extracted if applicable. 
2. To compare the rate of relapse in previously treated and new DR-TB patients
receiving the Bedaquiline containing regimen
DR-TB patients receiving the Bedaquiline containing regimen will be categorised as new and 
previously treated according to DR-TB category definitions. Information pertaining to monthly 
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culture results and culture conversion date will be reviewed from patient records. Relapse 
will be determined by an initial culture conversion documented in the patient record followed 
by positive monthly culture result. 
3. To compare the duration of Bedaquiline therapy in previously treated and new DR-
TB patients
DR-TB patients receiving the Bedaquiline containing regimen will be categorised as new or 
previously treated TB patients according to DR-TB category definitions. Information on the 
start date of Bedaquiline and the end date of Bedaquiline treatment will be extracted from 
patient records and the duration of Bedaquiline treatment (in days) will be calculated from 
the extracted data. 
4. To establish the severity of disease of previously treated and new DR-TB patients
DR-TB patients receiving the Bedaquiline containing regimen will be categorised as new or 
previously treated TB patients according to DR-TB category definitions. Information on 
baseline smear grading, baseline CXR findings and baseline resistance testing will be 
extracted from patient records in order to establish the severity of the disease. 
5 Data Management Plan 
5.1 Data Collection 
Patient information will be captured on paper-based Case Report Forms (CRF) (see 
Appendix1). To ensure that the data will be anonymised, patient identification numbers will 
be assigned to each of the audited files. The CRF will consist of specified data categories to 
assist with capturing of information, from diagnosis of DR-TB to treatment outcome. 
5.2 Data entering, storage and validation 
The information captured on the CRF will be checked for completeness. Any errors or 
omissions will be corrected immediately. The CRFs will be cross-referenced with the source 
documents to validate entries by the researcher. Study files will be labelled and kept in a 
secure, locked location with limited access. The anonymised data will be transferred onto an 
excel spreadsheet for further analysis using STATA version 15.0 software (StataCorp, Texas 
2019) on password protected laptop. An external hard drive will be used to backup data. 
6 Statistical Considerations 
Sample Size and Power 
Using WinPepi Version 11.65 software, a comparison of two independent groups, the group 
sample sizes were determined to be 76 (exposed) and 304 (unexposed) to achieve power of 
80% to detect a moderate difference in comparison between the two groups, with a level of 
significance of α 0.05. These computations were done based on the median survival times 
derived from a previous study.25 The study findings showed that culture conversion rates 
were 30.1% at 30 days, 56.7% at 60 days, 80.5% at 90 days and 91.2% at end of 
treatment.25 The median survival time of 180 days was based on the worst-case scenario 

















Large 0.333 180 60 145 29 116 
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Moderate 0.556 180 100 380 76 304 
Small 0.714 140 100 870 174 696 
Patient records will be systematically randomly sampled (every 2nd patient record) until the 
required sample size for the two groups are achieved. 
Data Analysis Plan 
Descriptive Analysis 
Patient characteristics will be summarised using frequencies and percentages for 
categorical variables and median and interquartile ranges (IQRs) for continuous 
variables. 
Unadjusted Analysis 
Odds ratios and Chi-squared tests will be used to determine associations between 
category of patient and conversion. Time to initial conversion of sputum culture will 
be analysed using Kaplan-Meier survival curves, which will be plotted, and the log 
rank test will be used to determine differences between groups. A p value ≤ 0.05 will 
be considered as statistically significant. 
Adjusted Analysis 
We will use Cox proportional hazards modelling to estimate hazard ratios, with time 
to sputum culture conversion as the endpoint, while controlling for confounding 
variables such as HIV status, ART, comorbidities. 
7 Ethical Considerations 
This protocol will be submitted to the Human Research Ethics Committee of Stellenbosch 
University for ethical approval. The protocol and a letter of request for permission to conduct 
the study will submitted to the CEO and management of Sizwe Tropical Disease Hospital. 
Informed Consent 
Retrospective patient record review, informed consent will not be possible from patients. 
Institutional permission to conduct the study will be requested to ensure access to patient 
records. An application for waive of consent will be applied for from the HREC, Stellenbosch 
University. The research involves use of routinely collected data and no participant contact 
will be sought. The waiver will not adversely affect the rights and welfare of the participants. 
Confidentiality 
All personal identifiers will be coded; all patient records will be assigned a personal 
identification number to protect data privacy and confidentiality. 
Standard of Care 
This is a retrospective file review; all patient identifiers will be anonymised. The data will be 
anonymised at the point of data collection no identifying information such as patient file 
numbers, names, or contact details will be recorded in any way during data collection. Once 
data has been collected, there is no way of tracing it back to the original patient/participant. 
Only aggregated data will be presented and anonymised in the reporting of findings i.e. no 
individual cases will be reported on. 
Inclusion of Women 
This study is a retrospective file review, all MDR-TB patients receiving the DR-TB 
Regimen containing Bedaquiline will be included in the study. 
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Exclusion of Children 
This study is a retrospective file review, all MDR-TB patients receiving the DR-TB 
Regimen containing Bedaquiline will be included in the study. Consent for inclusion 
will not be sought in the case of minors as this study is a retrospective review of 
patient records. 
Conflict of Interest 
No conflict of interests is anticipated. 
Dissemination of Findings 
The results of this study will be disseminated to Sizwe Tropical Disease Hospital, Dr N 
Ndjeka from the Department of Health, University of Stellenbosch, my peers (Conferences- 
Stellenbosch University; The Union and Journal Publication). 
8 Study Timelines 














X X X X 






9 Study Limitations 
Methodological limitation is that we will be using a surrogate marker for treatment 
response and not evaluating treatment outcomes. 
This study will provide information on clinically ill patients who would require in- 
patient care; thus, it would be difficult to generalise our findings to Primary Health 
Facilities. 
Due to retrospective file review, missing information may affect the quality of data. All 
source documents related to clinical monitoring contained in the patient file will be 
reviewed to ensure a complete data. 
10 Feasibility 
This study will be undertaken by reviewing patient records for a fixed duration. The 
proposed period for file review is adequate to obtain an adequate sample. The 
sample size of 380 required for the study is achievable. Since Sizwe Tropical 
Medicine Hospital is a Centre of Excellence, data on the severity of the disease, 
resistance profiles and co-morbidities will be available. 
Stellenbosch University  https://scholar.sun.ac.za
84 of 96 
11 Future Directions 
The findings of this study will provide added information on the programmatic 
implementation of the drug resistant policy framework regarding Bedaquiline 
containing regimens. 
12 Study Team 
The Principal Investigator will be responsible for data collection. The study 
supervisors will provide statistical and technical support. The hospital staff will assist 
with file retrieval. 
13 Institutional Research Environment 
The Clinical Epidemiology Department, Stellenbosch University, Western Cape, 
South Africa headed by Professor T Young provides academic support to both 
Masters and PhD students and is extensively involved and well experienced in 
conducting research. The division has a multi-disciplinary team with Biostatistical 
support provided by a team of statisticians. The division has access to internet, 
emails, photocopying facilities, telephone and fax services. The Clinical 
Epidemiology Department is well supported by Research Capacity Development 
Funding (RFO), ensuring capacity development of staff and post graduate students. 
The RFO provides support for annual research outputs reporting. 
14 Budget 
Period: January 2020 to August 2020 





Printing Case Report 
forms for data 
collection 
380 (0.45c/page x 4 




A4 files and 
stationery 









1 R20 000 R20 000 
Travel Fuel costs 40 (3.61/km x94km 




Internet, Email 3 250 R750 







1 1500 R1 500 
Publication Open Access 
Journal 
1 R12 000 R12 000 
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Total R50 482 
Budget Motivation: 
Equipment will be purchased to ensure that study data is safely and securely backed up. 
Travel costs to the study facility comprises fuel costs to cover 94km return trip per visit 
during the data collection phase of the study. 
Office supplies will be purchased to ensure that the paper based CRFs are securely filed 
and stored. 
Internet data is required during the data collection period and analysis for communication 
with statistician. 
Cell phone charges are based on average one-hour conference calls to update supervisors 
on study progress every two weeks upon ethics approval. 
An application for a Travel Grant will be made to Stellenbosch University to cover 
conference costs to attend The Union TB Conference in 2020. 
An application will be submitted to The Library at Stellenbosch University to assist with 
publication costs. 
The application for funding to The Harry Crossley Fund to cover operational costs of the 
study has been successful. 
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6a. If Yes to Q6. 





















8a. ART Start Date 
8b. 












D D M M Y Y Y Y 
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9. Date of DR-TB diagnosis
10. Laboratory diagnosis







12. DR-TB Treatment Start Date
















D D M M Y Y Y Y 
D D M M Y Y Y Y 
NVP 
LPV/r or ATV/r 
DTG 
8d. Last Viral Load 
<400=0 
>400=1
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17. Culture Conversion Date D D M M Y Y Y Y 
18. Time to Culture Conversion DAYS 
19. Bedaquiline start date D D M M Y Y Y Y 
20. Bedaquiline end date D D M M Y Y Y Y 
21. Duration of Bedaquiline DAYS 
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24. Treatment Regimen

















If Yes, specify 
26. Change of Regimen
No=0
Yes=1
If Yes, go to Q26.a 
26a. Was BDQ stopped 
No=0 
Yes=1 
If Yes, please specify reason 
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Project ID: 11609 
HREC Reference No: S19/09/177 
Project Title: Previous tuberculosis treatment and efficacy of Bedaquiline 
Dear Dr Amashnee Saimen 
The Response to Modifications received on 03/04/2020 16:48 was reviewed by members of Health Research Ethics Committee via expedited review 
procedures on 22/05/2020. 
Thank you for attending to the requested modifications, the research protocol is now finally approved. Please note the following information about 
your approved research protocol: 
Protocol Approval Date: 22 May 2020 
Protocol Expiry Date: 21 May 2021 
Please remember to use your Project ID 11609 and Ethics Reference Number S19/09/177 on any documents or correspondence with the HREC 
concerning your research protocol. 
Please note that the HREC has the prerogative and authority to ask further questions, seek additional information, require further modifications,  or monitor  
the conduct of your research and the consent process. 
After Ethical Review 
Translation of the informed consent document(s) to the language(s) applicable to your study participants should now be submitted to the HREC. 
Please note you can submit your progress report through the online ethics application process, available at: Links Application Form Direct Link and the 
application should be submitted to the HREC before the year has expired. Please see Forms and Instructions on our HREC website 
(www.sun.ac.za/healthresearchethics) for guidance on how to submit a progress report. 
The HREC will then consider the continuation of the project for a further year (if necessary). Annually a number of projects may be selected randomly for an 
external audit. 
Provincial and City of Cape Town Approval 
Please note that for research at a primary or secondary healthcare facility, permission must still be obtained from the relevant authorities (Western Cape 
Departement of Health and/or City Health) to conduct the research as stated in the protocol. Please consult the Western Cape Government website for 
access tothe online Health Research Approval Process, see: https://www.westerncape.gov.za/general-publication/health-research-approval-process. 
Research that will be conducted at any tertiary academic institution requires approval from the relevant hospital manager. Ethics approval is required 
BEFORE approval can be obtained from these healthauthorities. 
We wish you the best as you conduct your research. 
For standard HREC forms and instructions, please visit: Forms and Instructions on our HREC 
website https://applyethics.sun.ac.za/ProjectView/Index/11609 
If you have any questions or need further assistance, please contact the HREC office at 021 938 9677. 
Yours sincerely, 
Mrs. Brightness Nxumalo 
HREC 2 Coordinator 
National Health Research Ethics Council (NHREC) Registration 
Number: REC-130408-012 (HREC1)•REC-230208- 
010 (HREC2) 
Federal Wide Assurance Number: 00001372 
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531-4305
Fax: 011 531-4377 
Date: 10 September 2019 
Dr Amashnee Saimen 
RE: DOES PREVIOUS TUBERCULOSIS TREATMENT HISTORY INFLUENCE TIME TO CULTURE CONVERSION FOR PATIENTS RECEIVING 
A BEDAQUILINE CONTAINING REGIMEN AT SIZWE 
TROPICAL DISEASE HOSPITAL, SOUTH AFRICA? 
Sizwe Tropical Disease Hospital supports the study titled: "Does previous tuberculosis treatment history influence time to culture conversion 
for patients receiving a Bedaquiline containing regimen at Sizwe Tropical Disease Hospital, South Africa?", to be conducted in our facility. 
Kind regards 
Dr. M.C. Louw 
CEO: Sizwe Tropical Disease Hospital 
,   :i.AUTENGHEALTH DEPARTMENT l 
Sizwe Tropical Disease Hospit al 
Private Bag X2 
Sandringham 2131 
DR. M. C. LOUW 
Chief Executive Officer 
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